Methods for simultaneous expansion of multiple immune cell types, related compositions and their use in cancer immunotherapy - Patents.com
By co-expanding NK and T cells with engineered receptors and controlled cytokine release, the therapy addresses the limitations of traditional cancer treatments and immunotherapy, offering enhanced cancer cell targeting with reduced side effects.
Patent Information
- Application Number
- JP2021529436
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-11-26
- Filing Date
- 2019-11-22
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2039-11-22
AI Technical Summary
Traditional cancer treatments such as surgery, chemotherapy, and radiation therapy are often ineffective and can cause severe side effects, while current immunotherapy methods using T cells alone can lead to adverse immune responses like cytokine release syndrome (CRS).
Simultaneously expanding and combining populations of natural killer (NK) cells and T cells in specific ratios, with genetically engineered receptors to target cancer cells, while modulating T cell cytokine release to enhance cytotoxicity and reduce side effects.
The combined NK and T cell therapy achieves robust and sustained cytotoxicity against cancer cells, reducing the risk of adverse immune effects like CRS, and provides a safer and more effective cancer treatment.
Smart Images

Figure 0007584414000001 
Figure 0007584414000002 
Figure 0007584414000003
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of priority to U.S. Provisional Patent Application No. 62 / 771,482, filed November 26, 2018, the entire contents of which are incorporated herein by reference.
[0002] Inclusion by citation of material in an ASCII text file This application incorporates by reference the sequence listing contained in the following concurrently filed ASCII text file: Filename: NKT0028WO_ST25.txt; created on November 22, 2019, size 9.4KB. [Background technology]
[0003] background Malignant tumors are the result of uncontrolled proliferation of cells in the body. Similarly, many diseases or infectious diseases are caused by the dysregulation of normal tissue proliferation and cell death. Although surgical methods or drug therapy have long been used as the first-line treatment, immunotherapy is a new option for treating cancerous or diseased tissue. Summary of the Invention
[0004] overview Traditional anti-cancer drug therapy relies on surgical approaches, radiation therapy, chemotherapy or a combination of these methods. Similarly, many diseases or infections are treated with traditional drug therapy, but the development of biological agents has recently changed the way they are treated. Once the mechanisms of certain cancers have been elucidated through research, targeted cancer therapies have been developed. Targeted therapies are cancer treatments that use specific drugs to suppress or block the growth of cancer cells by targeting specific genes or proteins found in cancer cells or cells that support the growth of cancer (such as blood vessel cells). Recently, genetic engineering has made it possible to develop methods to use specific aspects of the immune system to fight cancer. In some cases, a patient's own immune cells are modified to specifically eradicate the patient's type of cancer. As detailed below, various types of immune cells can be used, such as T cells or natural killer (NK) cells.
[0005] In some embodiments, methods for co-expansion of multiple populations of immune cells are provided. In one embodiment, two, three, four or more different cell types are (i) co-expanded together or (ii) co-expanded in parallel and then combined. In some embodiments, NK cells and T cells are expanded together or separately and combined at a ratio of NK cells:T cells of about 5:1, about 10:1, about 20:1, such as 5:1, 7:1, 10:1, 12:1, 15:1, 17:1, 20:1 or any ratio therebetween. In another embodiment, there are at least two times more NK cells than T cells. These ratios (more NK cells than T cells) are particularly advantageous in some embodiments, allowing for a robust acute anti-tumor response (due to more expanded NK cells and their cytotoxic activity) in combination with long-term cytotoxicity from T cells. In some embodiments, not only is T cell proliferation suppressed, but the inhibitory effect of NK cells on T cells modulates T cell cytokine release compared to T cell-only approaches. In T cell only therapy, various cytokines released from T cells act in an autocrine manner to upregulate T cell proliferation and activity. Left unchecked proliferation and activation can lead to various side effects such as neurotoxicity, "target / non-target" recognition, anaphylaxis, and even cytokine release syndrome (CRS, a potentially life-threatening systemic inflammatory response seen after administration of antibody, adoptive T cell therapy). In some embodiments, T cells still release certain cytokines, but rather than causing T cell stimulation (and release of further cytokines that can lead to CRS), these cytokines act to actively stimulate NK cells. Thus, in some responses, NK cells attenuate the ability of T cells to self-stimulate by inducing proliferation (and more cytotoxicity). Thus, the presence of NK cells reduces the proliferative and cytokine releasing activity of T cells. Thus, in some embodiments, the combination of NK cells and T cells provides a more effective and safe cancer immunotherapy product.In some embodiments, the T cells comprise one, two, three or more of the following subtypes: cytotoxic T cells, helper T cells, NKT cells, or gamma delta T cells. In one embodiment, the collective total of multiple subtypes is calculated in a ratio described herein, including but not limited to, 5-10:1, 10-15:1, 15-20:1. In another embodiment, the collective total of one of the subtypes is calculated in a ratio described herein, including but not limited to, 5:1.
[0006] In some embodiments, the first cell type is combined with the second cell type in a ratio of about 5-10:1, e.g., 5:1, 6:1, 7:1, 8:1, 9:1, and 10:1. In some embodiments, the first cell type is combined with the second cell type in a ratio of about 11-15:1, e.g., 11:1, 12:1, 13:1, 14:1, and 15:1. In some embodiments, the first cell type is combined with the second cell type in a ratio of about 16-20:1, e.g., 16:1, 17:1, 18:1, 19:1, and 20:1. In another embodiment, there is at least 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, or more of cell type 1 over cell type 2. In another embodiment, a third cell type is also included. In one embodiment, cell type 1 includes NK cells and cell type 2 includes T cells. In other embodiments, other cell types are used.
[0007] Thus, the present invention provides methods for generating mixed populations of immune cells (e.g., engineered immune cells) having specific relative proportions of subpopulations of the mixed population. In some embodiments, these methods allow for the generation of a cell population that provides a robust cytotoxic effect against target cells, such as tumor cells, while reducing the likelihood of adverse immune effects that may occur if a particular subpopulation of engineered immune cells is more abundant. In some embodiments, a method for generating a mixed population of immune cells comprising at least two subpopulations of engineered immune cells comprises isolating a mononuclear cell population from a blood sample, wherein the isolated mononuclear cell population comprises at least a first and a second immune cell subpopulation, isolating a first subpopulation of immune cells from the isolated mononuclear cells, and culturing the first subpopulation of isolated immune cells in a culture vessel with a population of feeder cells, wherein the feeder cells express at least one molecule for stimulating proliferation of natural killer (NK) cells within the first immune cell subpopulation to generate an expanded population of NK cells. The present invention provides a method for producing a mixed population of genetically modified immune cells, the method comprising: isolating a second immune cell subpopulation from said isolated mononuclear cells, culturing said second immune cell subpopulation in a culture vessel with at least one molecule that stimulates proliferation of T cells in said second immune cell subpopulation to expand a population of T cells, genetically engineering NK cells and / or T cells to express a protein or drug that enhances cytotoxicity and / or reduces side effects, and combining a portion of the genetically engineered cytotoxic NK cells with a portion of the genetically engineered cytotoxic T cells to generate a mixed population of genetically modified immune cells. In some embodiments, the combination of two (or more) expanded genetically modified immune cells is performed in vitro, while in other embodiments, the combination is performed in vivo (e.g., by combined or sequential administration of expanded cell types).
[0008] In some embodiments, the at least one molecule for stimulating NK cells is selected from 4-1BB ligand (4-1BBL), interleukin 15 (IL-15), and combinations thereof. In some embodiments, the molecule for stimulating NK cell proliferation comprises a combination of 4-1BBL and IL15. In some embodiments, the interleukin 15 (IL-15) is membrane-bound to the feeder cells. In some embodiments, the culture of the first subpopulation of isolated immune cells further comprises adding one or more of soluble interleukin 2, soluble interleukin 12, soluble interleukin 18, or combinations thereof to the culture. In some embodiments, the at least one molecule for stimulating T cell proliferation comprises one or more of an antibody against CD3 or an antibody against CD28. In some embodiments, the at least one molecule for stimulating T cell proliferation comprises an anti-CD3 antibody. In further embodiments, a mixture of an anti-CD3 antibody and an anti-CD28 antibody is used. In some embodiments, the at least one molecule for stimulating T cell proliferation comprises an anti-CD28 antibody. Depending on the embodiment, the antibody against CD3 may include OKT3 antibody. In some embodiments, OKT3 antibody, other anti-CD3 antibody or anti-CD28 antibody is expressed by feeder cells that are co-cultured with the second subpopulation of immune cells. In further embodiments, the antibody or other stimulatory molecule is bound to a solid support. The solid support may include a culture vessel, a biocompatible bead containing a label, or a superparamagnetic bead, depending on the embodiment. Thus, in some embodiments, the stimulatory molecule is provided by being expressed by the feeder cells, while in some embodiments, cell-free expansion is used (e.g., the stimulatory molecule is added to the culture medium or otherwise bound to a solid support that is not a feeder cell).
[0009] In some embodiments, the method includes introducing into the expanded NK cell population a nucleic acid encoding a genetically modified receptor configured to bind to a target expressed by the cancer cell and induce cytotoxic activity against the cancer cell upon binding, to generate genetically modified cytotoxic NK cells. Similarly, in some embodiments, the method further includes introducing into the expanded T cell population a nucleic acid encoding a genetically modified receptor configured to bind to a target expressed by the cancer cell and induce cytotoxic activity against the cancer cell upon binding, to generate genetically modified cytotoxic cells. In some embodiments, the NK cells and T cells are introduced with the same genetically modified receptor, and in other embodiments, the NK cells and T cells are introduced with different genetically modified receptors. In some embodiments, when cells of additional subtypes are used in the mixed population, the cells may be designed to express the same genetically modified receptor as the NK cells and / or T cells, or may be designed to express a different receptor type. In some embodiments, the nucleic acid introduced into the expanded cells encodes a chimeric antigen receptor (CAR). CARs can be receptors for various targets expressed by tumor cells, including those specifically expressed by tumor cells as well as those overexpressed by tumor cells (thus limiting the targeting of native cells with markers).In some embodiments, CARs are receptors for CD19, CD123, BCMA, galactin, Ral-B, FLT3, CD70, DLL3, CD5, GUCY2C, EGFR, KREMEN2, PSMA, ALPPL2, CLDN6, CLDN18, GPR143, GRM8, LPAR3, GD2, ADAM12, LECT1 or TMEM186.In some embodiments, CARs are receptors for one or more NKG2D ligands, including but not limited to MICA, MICB, ULBP1, ULBP2, ULBP3, ULBP4, ULBP5 and / or ULBP6. In some embodiments, the genetically modified cells are configured to express CARs against different targets, including in some embodiments a mixture of NK cells and T cells collectively directed against two, three, four or more different tumor targets.In some embodiments, the CAR is a receptor for CD19. In some embodiments, each subpopulation of the mixed population expresses an anti-CD19 CAR. In some embodiments, the anti-CD19 CAR comprises an OX40 costimulatory domain and a CD3ζ signaling domain operably linked to an anti-CD19 scFv. In some embodiments, the anti-CD19 CAR is encoded by a nucleic acid having at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:1. In some embodiments, the anti-CD19 CAR comprises an amino acid sequence having at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:2.
[0010] In some embodiments, the genetically modified cytotoxic NK cells and the genetically modified cytotoxic T cells are combined in a ratio such that (i) the genetically modified NK cells exhibit enhanced cytotoxicity against cancer cells compared to the genetically modified NK cells alone, (ii) the genetically modified cytotoxic T cells can increase the number of proliferating genetically modified NK cells, and / or (iii) the genetically modified T cells exhibit reduced cytokine release compared to the genetically modified T cells alone. The ratio used can be adjusted for a given patient, tumor type, severity or tumor progression stage, or can be based on other diagnostic or prognostic factors. In some embodiments, the ratio of genetically modified NK cells to genetically modified T cells is about 5:1. In other embodiments, other ratios are used. For example, in some embodiments, the ratio of the first cell type to the second cell type is about 2:1, about 4:1, about 6:1, about 8:1, about 10:1, about 12:1, about 14:1, about 16:1, about 18:1, about 20:1 or more (or any ratio therebetween as described).
[0011] In some embodiments, the blood sample from which the immune cells are isolated is a peripheral blood sample. In further embodiments, the blood sample is an umbilical cord blood sample. In some embodiments, the mixed population of genetically modified immune cells is about 1x10 7 ~ approx. 1x10 10 genetically modified cytotoxic NK cells and approximately 1x10 5 ~ approx. 1x10 8 and genetically modified cytotoxic T cells. As described herein, various embodiments combine two or more immune cell types in a ratio that allows for effective cytotoxicity against target tumor cells while reducing or eliminating the risk of adverse immune effects, including CRS. In some embodiments, the mixed population of genetically modified immune cells exhibits a rapid cytotoxic effect against tumor cells, followed by enhanced durable cytotoxic effect against tumor cells. In some embodiments, the NK portion of the mixed population of genetically modified immune cells has a longer duration of durable cytotoxic effect against tumor cells compared to NK cells or T cells alone.
[0012] In some embodiments, a mixed population of genetically modified cytotoxic immune cells is provided, comprising a first subpopulation of immune cells comprising NK cells, wherein the NK cells are engineered to express a genetically modified receptor configured to bind to a target expressed by a cancer cell and elicit cytotoxic activity against the cancer cell upon binding, wherein the first subpopulation is greater than or equal to about 1×10 8 ~ approx. 1x10 10 and a second subpopulation comprises immune cells including T cells, wherein the T cells are engineered to express a genetically engineered receptor configured to bind to a target expressed by the cancer cell and elicit cytotoxic activity against the cancer cell upon binding, the second subpopulation comprising approximately 1x10 4 ~ approx. 1x10 6 The mixed population of genetically modified NK cells and genetically modified T cells comprises T cells, and at a given effector to target cell ratio, the mixed population exhibits greater cytotoxicity against cancer cells than either NK cells alone or T cells alone at an equivalent effector to target ratio.
[0013] As described above, in some embodiments, the genetically modified receptor comprises a chimeric antigen receptor that can be directed against various targets, such as CD19, CD123, galactin, Ral-B, FLT3, CD70, DLL3, CD5, GUCY2C, EGFR, KREMEN2, PSMA, ALPPL2, CLDN6, CLDN18, GPR143, GRM8, LPAR3, GD2, ADAM12, LECT1 or TMEM186. In some embodiments, each subpopulation of the mixed population expresses an anti-CD19 CAR. In some embodiments, the anti-CD19 CAR comprises an OX40 costimulatory domain and a CD3ζ signaling domain operably linked to an anti-CD19 scFv. In some embodiments, the anti-CD19 CAR is encoded by a nucleic acid having at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:1. In some embodiments, the anti-CD19 CAR comprises an amino acid sequence having at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO:2.
[0014] The present invention further provides a method for expanding a mixed population of immune cells comprising at least two subpopulations of immune cells, comprising isolating a population of mononuclear cells from a blood sample; dividing the isolated mononuclear cell population into at least a first subpart and a second subpart; culturing the first subpart of isolated mononuclear cells with a first population of feeder cells in a culture vessel comprising a first medium, wherein the first population of feeder cells expresses at least one molecule for stimulating proliferation of natural killer (NK) cells in the first subpart of isolated mononuclear cells and / or the first medium comprises at least one molecule for stimulating proliferation of natural killer (NK) cells in the first subpart of isolated mononuclear cells, wherein the at least one molecule is selected from the group consisting of 4-1BB ligand (4-1BBL), interleukin-15 (IL-15), and / or IL-2. 15) and combinations thereof, thereby generating an expanded population of NK cells; culturing a second subpart of the isolated mononuclear cells with a second population of feeder cells in a culture vessel containing a second culture medium, wherein the second population of feeder cells express at least one molecule for stimulating proliferation of one or more subpopulations of T cells in the second subpart of the isolated mononuclear cells and / or the second culture medium comprises at least one molecule for stimulating proliferation of one or more subpopulations of T cells in the second subpart of the isolated mononuclear cells, thereby generating an expanded population of one or more subpopulations of T cells; and combining at least a portion of the expanded population of NK cells with at least a portion of the expanded population of one or more subpopulations of T cells to generate a mixed population of immune cells comprising at least two subpopulations of immune cells.
[0015] In some embodiments, the mixed population comprises a higher percentage of NK cells compared to the combined percentage of one or more subpopulations of T cells, in some embodiments, one or more subpopulations of T cells comprise gamma-delta T cells.
[0016] The present invention provides a mixed population of immune cells produced by the methods described herein. In some embodiments, the mixed population of immune cells is adapted for use in the treatment of tumors, whether the tumor is a solid tumor or a suspension tumor. The present invention also provides the use of the mixed population of immune cells described herein for the treatment of cancer. In some embodiments, the present invention provides the use of the mixed population of immune cells in the manufacture of a medicament for the treatment of cancer.
[0017] Also, in some embodiments, a combination of genetically modified NK cells and genetically modified T cells is provided, wherein the ratio of NK cells to T cells is at least 5:1. In some embodiments, a combination of genetically modified NK cells and genetically modified T cells is provided, wherein the ratio of NK cells to T cells is at least 10:1. In some embodiments, a combination of genetically modified NK cells and genetically modified T cells is provided, wherein the ratio of NK cells to T cells is at least 12:1. In some embodiments, a combination of genetically modified NK cells and genetically modified T cells is provided, wherein the ratio of NK cells to T cells is at least 15:1. In some embodiments, a combination of genetically modified NK cells and genetically modified T cells is provided, wherein the ratio of NK cells to T cells is at least 20:1.
[0018] In some embodiments, the combination of cells at or about the ratios shown induces enhanced cytotoxic activity of genetically modified NK cells against target tumors. In some embodiments, the combination of cells at or about the ratios shown induces enhanced persistence of cytotoxic activity of genetically modified NK cells against target tumors compared to genetically modified NK cells alone. In some embodiments, the combination of cells at or about the ratios shown induces reduced cytokine release by genetically modified T cells compared to genetically modified T cells alone. In some embodiments, the combination of cells at or about the ratios shown induces reduced proliferation of genetically modified T cells compared to genetically modified T cells alone.
[0019] In some embodiments, a method of treating cancer using a mixed population of cells as described herein is provided. As described herein, in some embodiments, the combination of cells is achieved by mixing cell types in a desired ratio after expansion and before delivery to a patient. In some embodiments, the combination is achieved by administration (e.g., the required number of cells from each cell type is administered so that the desired ratio is achieved in vivo). In some embodiments, the treatment method further comprises administration of IL2. In embodiments that include generating the resulting combination in vivo, this may be achieved by administering the first cell type first, or by administering the second cell type first. In some embodiments, administration of the first type of genetically modified immune cells can provide an improved microenvironment for the second type (or third type, etc.) of immune cells.
[0020] In some embodiments, methods are provided for the co-expansion of multiple immune cell populations, for example, co-expansion of NK cells and T cells. Also provided are immune cell populations comprising a mixture of two or more immune cell subpopulations, and methods and uses of such compositions for the treatment of cancer and other diseases or causes of damaged tissue. In some embodiments, the mixed cell population of NK cells and T cells advantageously provides a dual effect on target cells, for example, a rapid phase of cytotoxic effect induced by NK cells combined with a longer period of tumor control as a result of T cell activity. Advantageously, in some embodiments, the two types of cells are produced together in a single process and can be administered in combination with each other. In some embodiments, in a first part of the expansion process, NK cells are produced, then T cells are produced, and in a second part of the expansion process, the resulting NK cell population and T cell population are combined to achieve the desired ratio of NK:T cells. In a further embodiment, NK cells and T cells are cultured together and the methodology adjusted to control the expansion rate of one cell type relative to the other (as well as that of any third, fourth or more cell types included in the mixture) so that a desired ratio is achieved after the combined expansion culture process.
[0021] In some embodiments, methods are provided that allow for the expansion and transfer of both NK cells and T cells (and additional immune cell types, if desired) using optimized constructs within defined parameters, with the resulting composite cell population advantageously exhibiting a synergistic effect on target cells that represents the optimized activity of each of the constituent immune cell subpopulations.
[0022] According to some embodiments, a method for expanding a mixed population of immune cells comprising at least two subpopulations of immune cells is provided, comprising isolating a mononuclear cell population from a blood sample, culturing the isolated mononuclear cells in a culture vessel with a population of feeder cells, the feeder cells being configured to express at least one molecule for stimulating the proliferation of NK cells, exposing the mononuclear cells co-cultured with the feeder cells to at least one molecule for stimulating the proliferation of T cells in the isolated mononuclear cells, and culturing the mononuclear cells co-cultured with the feeder cells and exposed to at least one molecule for stimulating the proliferation of T cells for a period of time sufficient to allow the proliferation of both the NK cell and T cell subpopulations, thereby generating a mixed population of immune cells comprising at least two subpopulations of immune cells. In some embodiments, the isolated mononuclear cell population is characterized in that it comprises at least two different types of immune cells, such as, for example, NK cells and one or more T cell subtypes (e.g., cytotoxic T cells, NKT cells, gamma delta T cells, etc.).
[0023] In some embodiments, the methods described herein may further comprise enriching the isolated mononuclear cells to increase the relative proportion of NK cells compared to the isolated mononuclear cell population. In some embodiments, the methods described herein may further comprise depleting the isolated mononuclear cells to decrease the relative proportion of T cells compared to the isolated mononuclear cell population.
[0024] In some embodiments, the at least one molecule for stimulating the proliferation of natural killer (NK) cells in the isolated mononuclear cells is 4-1BB ligand (4-1BBL), interleukin 15 (IL-15), or a combination thereof. In some embodiments, other stimulatory molecules, including other interleukins, may be used. In some embodiments, such stimulatory molecules are added to the culture medium in addition to or instead of the expression of stimulatory molecules by the feeder cells. In some embodiments, the at least one molecule for stimulating the proliferation of NK cells comprises a combination of 4-1BBL and IL15. In some embodiments, interleukin 15 (IL-15) is membrane-bound to the feeder cells.
[0025] In some embodiments, the at least one molecule for stimulating the proliferation of T cells comprises an antibody that interacts with a portion of the T cell receptor on T cells. In some embodiments, the antibody used is an antibody against CD3 or against CD28. In some embodiments, a bispecific antibody (e.g., an antibody that targets both CD3 and CD28) is used. In some embodiments, the antibody comprises an OKT3 antibody. In some embodiments, the CD3, CD28 and / or OKT3 antibody is expressed by feeder cells. In further embodiments, the CD3, CD28 and / or OKT3 antibody is provided in the culture medium.
[0026] In some embodiments, the at least one molecule for stimulating T cell proliferation comprises an anti-CD3 antibody. In some embodiments, the at least one molecule for stimulating T cell proliferation comprises an anti-CD28 antibody. In some embodiments, the at least one molecule for stimulating T cell proliferation comprises a mixture of anti-CD3 antibody and anti-CD28 antibody. In some embodiments, the antibody is bound to a solid support. In some embodiments, the solid support comprises a culture vessel, a biocompatible bead comprising a label, or a superparamagnetic bead.
[0027] In some embodiments, exposing the mononuclear cells co-cultured with feeder cells to at least one molecule for stimulating the proliferation of T cells in isolated mononuclear cells is performed at the same time that the mononuclear cells are co-cultured with feeder cells. However, in some embodiments, the exposure is performed sequentially (e.g., before or after co-culture). For example, in some embodiments, exposing the mononuclear cells co-cultured with feeder cells to at least one molecule for stimulating the proliferation of T cells in isolated mononuclear cells is performed at a later time point than the mononuclear cells are co-cultured with feeder cells. In some embodiments, the later the time that the mononuclear cells co-cultured with feeder cells are exposed to at least one molecule for stimulating the proliferation of T cells is inversely correlated with the degree of proliferation of T cells from the mononuclear cell population. Thus, in some embodiments, the timing of exposure is used to adjust the degree of proliferation of T cells (or subtypes of T cells) in the resulting mixed cell population.
[0028] In some embodiments, the ratio of feeder cells to mononuclear cells ranges from about 10:1 to 1:10. In some embodiments, the ratio of feeder cells to mononuclear cells is about 1:1. Other ratios are used in some embodiments, for example, the ratio of feeder cells:mononuclear cells is 1000:1, 500:1, 250:1, 100:1, 50:1, or any other ratio between and including the recited ratios.
[0029] In some embodiments, the blood sample is a peripheral blood sample. In some embodiments, the blood sample is an umbilical cord blood sample. In some embodiments, the blood sample is from fetal-maternal tissue, such as placenta. In some embodiments, the source is used to generate a mixed immune cell population that is allogeneic with the recipient. In some embodiments, the recipient is a donor. In some embodiments, the blood sample and / or the expanded mixed population is stored (e.g., frozen) until ready for delivery to the recipient.
[0030] In some embodiments, the mixed population of immune cells has a ratio of NK cells to T cells (including various T cell subpopulations) ranging from about 100:1 to about 1:100. In some embodiments, approximately equal amounts of NK cells and T cells are used, such that the mixed population of immune cells has a ratio of NK cells to T cells of about 1:1.
[0031] In some embodiments, a mixed population of immune cells having a ratio of NK cells to T cells of about 1:1 to about 100:1 exhibits a rapid cytotoxic effect against tumor cells compared to NK cells alone or T cells alone, followed by a sustained cytotoxic effect against tumor cells. In some such embodiments, a mixed population of immune cells having a ratio of NK cells to T cells of between about 1:1 to about 1:100 exhibits a longer sustained cytotoxic effect against tumor cells compared to NK cells alone or T cells alone.
[0032] Also, in some embodiments, the present invention provides a population of feeder cells configured to stimulate the proliferation of at least two subpopulations of immune cells from a mononuclear cell population, wherein the feeder cells express at least one signal for stimulating the proliferation of NK cells and at least one signal for stimulating the proliferation of T cells (or a subpopulation of T cells), wherein the at least one signal for the proliferation of NK cells is selected from 4-1BB ligand (4-1BBL), interleukin 15 (IL-15) and combinations thereof, and wherein the at least one signal for the proliferation of NK cells is selected from a molecule that interacts with CD3 of the T cell receptor, and optionally a molecule that interacts with CD28 on T cells.
[0033] The present invention also provides the use of such a population of feeder cells to generate a mixed cell population comprising NK cells and T cells. In some embodiments, the proportion of NK cells in the mixed cell population is greater than about 10% of the total, and the proportion of T cells in the mixed cell population is greater than about 30% of the total. In some embodiments, the proportion of NK cells in the mixed cell population and the proportion of T cells in the mixed cell population are between about 40% and 60% of the total, respectively.
[0034] In some embodiments, a mixed population of NK cells and T cells (including a subpopulation of T cells) is also provided, where the percentage of NK cells in the mixed cell population is greater than about 10% of the total, and the percentage of T cells in the mixed cell population is greater than about 30% of the total. In some embodiments, the percentage of NK cells in the mixed cell population and the percentage of T cells in the mixed cell population are between about 40% and 60% of the total, respectively. In some embodiments, the mixed cell population exhibits bi-phasic cytotoxicity kinetics against target cells. In some such embodiments, the bi-phasic cytotoxicity kinetics includes a rapid and intense initial cytotoxicity phase followed by a lower intensity cytotoxicity phase. In some embodiments, the target cells include tumor tissue. In some embodiments, the tumor tissue is a solid tumor, while in further embodiments, the tumor tissue is a suspension tumor (e.g., a hematological tumor).
[0035] The invention also provides the use of a mixed population of NK cells and T cells for the treatment of cancer and / or in the manufacture of a medicament for the treatment of cancer.
[0036] Some additional embodiments provided herein relate to a method for expanding a mixed population of immune cells comprising at least two subpopulations of immune cells, the method comprising isolating a population of mononuclear cells from a blood sample, wherein the isolated population of mononuclear cells comprises at least two different types of immune cells, and culturing the isolated mononuclear cells with a population of feeder cells in a culture vessel comprising a culture medium, wherein the culturing is performed for a time sufficient to allow expansion of both the NK cell subpopulation and the T cell subpopulation, thereby generating a mixed population of immune cells comprising the at least two subpopulations of immune cells.
[0037] In some embodiments, the feeder cells express at least one molecule for stimulating the proliferation of natural killer (NK) cells in the isolated mononuclear cells, and / or the culture medium comprises at least one molecule for stimulating the proliferation of natural killer (NK) cells in the isolated mononuclear cells. In some embodiments, the at least one molecule is selected from 4-1BB ligand (4-1BBL), interleukin 15 (IL-15), and combinations thereof. In some embodiments, the feeder cells express at least one molecule for stimulating the proliferation of T cells or one or more subpopulations of T cells in the isolated mononuclear cells, and / or the culture medium comprises at least one molecule for stimulating the proliferation of T cells or one or more subpopulations of T cells in the isolated mononuclear cells. In some embodiments, the one or more subpopulations of T cells are one or more of cytotoxic T cells, natural killer T cells (NKT cells), effector T cells, helper T cells, memory T cells, regulatory T cells, gamma delta T cells, mucosal-associated invariant T cells. In some embodiments, the blood sample is an umbilical cord blood sample.
[0038] The present invention also provides a method for expanding a mixed population of immune cells comprising at least two subpopulations of immune cells, the method comprising isolating a population of mononuclear cells from a blood sample, wherein the isolated population of mononuclear cells comprises at least two different types of immune cells, dividing the isolated population of mononuclear cells into at least a first subpart and a second subpart, culturing the first subpart of the isolated mononuclear cells with a first population of feeder cells in a culture vessel comprising a first medium, culturing the second subpart of the isolated mononuclear cells with a second population of feeder cells in a culture vessel comprising a second medium, and combining at least a portion of the expanded population of NK cells with at least a portion of the expanded subpopulation of one or more T cells to generate a mixed population of immune cells comprising at least two subpopulations of immune cells.
[0039] In some embodiments, the first population of feeder cells express at least one molecule for stimulating proliferation of natural killer (NK) cells in the first subpart of isolated mononuclear cells and / or the first culture medium comprises at least one molecule for stimulating proliferation of natural killer (NK) cells in the first subpart of isolated mononuclear cells. In some embodiments, the at least one molecule is selected from 4-1BB ligand (4-1BBL), interleukin 15 (IL-15) and combinations thereof, and the second population of feeder cells expresses and / or the second culture medium comprises at least one molecule for stimulating proliferation of one or more subpopulations of T cells in the second subpart of isolated mononuclear cells.
[0040] In some embodiments, the mixed population comprises a higher percentage of NK cells compared to the combined percentage of one or more subpopulations of T cells. In some embodiments, one or more subpopulations of T cells comprises gamma-delta T cells.
[0041] Also provided in some embodiments is a composition or use thereof in the treatment of cancerous tumors according to any one of the embodiments described herein. [Brief description of the drawings]
[0042] The following description of the figures relates to tests and results that represent non-limiting aspects of the invention described herein. [Figure 1] Figures 1A-1D are schematic diagrams of donor cell composition from four healthy donors. Figure 1A shows the approximate percentage distribution of T cells, NK cells and other cells in blood samples from the first donor. Figures 1B, 1C and 1D show the corresponding data from three additional donors. [Diagram 2] FIG. 2 shows a schematic process flow diagram by which various K562 clones effective for co-expansion of NK and T cells can be identified according to certain embodiments described herein. That is, a pooled population of K562 is subjected to limiting dilution, and a selected number of individual clones are tested for their ability to expand both NK and T cells in culture. Blood samples from four donors shown in FIGS. 1A-1D are used. The feeder cell lines (and clones) used for co-expansion of NK and T cells are modified K562 cells genetically engineered to express 41BBL, membrane-bound IL-15, and membrane-bound anti-CD3 scFv OKT3. The feeder clones are treated with mitomycin C and seeded at 5×105 cells per well in the culture vessel. On day 0 of culture, donor peripheral blood mononuclear cells are seeded in the same wells as the feeder clones at a density of 5×105 cells per well. Interleukin 2 (IL-2) is added at 40 units / mL on co-culture day 0, this is repeated on co-culture day 4, and again on co-culture day 6, with 400 units / mL of IL-2 added. Cells are expanded from co-culture days 7 to 13, and the ratio of NK cells to T cells is assessed during this period. Co-culture days 14 to 20 are used to determine the final resulting cell populations with a ratio of NK cells to T cells based on variables adjusted earlier in the co-culture process, such as the introduction of a secondary stimulus to supplement the stimulation provided by the modified K562 cells.
[0043] [Diagram 3]Figures 3A-3B show data relating to the increase in fold change in proliferation of NK or T cells obtained from four donors after 7 days of culture with 24 different K562 clones. Figure 3A shows that certain K562 clones exhibited similar proliferation efficiency as when using native genetically modified K562 stimulatory feeder cell lines (e.g., a mixed population of genetically modified K562 cells rather than a population consisting of a single replicating clone). Figure 3B shows that each clone tested has the ability to potently stimulate T cell proliferation. [Figure 4] 4A-4B show data relating to cell composition obtained from four different donors after seven days of expansion culture with 24 different K562 clones. FIG. 4A shows data on the percentage of NK cells present in the expanded cell population after seven days of culture obtained from each of the four donors when expanded with each of the K562 populations of 24 individual clones used as feeder cells. FIG. 4B shows corresponding data for the percentage of T cells shown after seven days of culture. These data show that, generally, the cell composition obtained after seven days of culture reflects the initial (e.g., starting) NK:T cell ratio. In some embodiments, described in more detail below, the methods described herein allow for manipulation of either the incoming ratio of NK cells:T cells or, by modification of the method, allowing differential expansion of NK cells and / or T cells to obtain a desired final NK cell to T cell ratio. [Diagram 5]FIG. 5 shows a schematic of an expansion protocol according to some embodiments described herein, in which supplemental stimulation sources are added to the culture at variable time points. Similar to FIG. 2, FIG. 5 shows a timeline of the three stages of the expansion protocol. Again at time 0, the culture is supplemented with low doses of IL-2, which is repeated on day 4, and again on day 6 (high doses of IL-2). The schematic in FIG. 5 shows a matrix illustrating the addition of supplemental stimulation sources for T cell proliferation (e.g., CD3 / CD28 beads) or none at all ("no beads", control) during any of the first six days of culture. FACS analysis is performed over time at several steps during the co-culture to assess the relative proliferation and transduction efficiency of NK and T cells.
[0044] [Figure 6] Figures 6A-6B show data related to NK cell and T cell proliferation upon addition of supplemental proliferation stimuli. Figure 6A shows the changes in NK cells after 7 days of culture assessed with and without beads, and the day CD3 / CD28 beads (supplemental stimulus for T cells) were added to the co-culture. Figure 6B shows the corresponding data on T cell proliferation. [Figure 7] Figures 7A-7D show data relating to the ability to simultaneously transduce both NK and T cells with a vector containing an exogenous gene for expression, and the ability of both cell types to maintain expression of the transduced gene, relative to the time of addition of CD3 / CD28 beads to the culture. Figures 7A and 7B show the transduction efficiency of each cell type in four donors three days after transduction, as measured by flow cytometry. Figures 7C and 7D show the maintenance of expression at seven days after transduction. [Figure 8] 8A-8D show data regarding the change in the ratio of NK cells to T cells upon longer co-culture expansion times. [Figure 9] 9A-9C are schematic diagrams of various genetically modified cells for evaluating mixed populations of NK / T cells in vitro and / or in vivo. [Figure 10]FIG. 10 shows data regarding the cytotoxic effects of NK cells, T cells and mixed populations of NK cells+T cells in a re-exposure assay. [Figure 11] FIG. 11 shows data regarding the evaluation of immune cell populations according to embodiments described herein in an in vitro 3-D culture environment.
[0045] [Figure 12] Figure 12A shows a test setup designed to identify the effective ratio of NK cells containing chimeric antigen receptors and T cells containing chimeric antigen receptors as a combination therapy against target tumor cells. Figure 12B shows the cytotoxicity measured by IncuCyte assay (loss of signal indicates cytotoxic effect against target cells). Boxes are added to identify the E:T and NK:T ratios that show maximum cytotoxicity against Nalm6 target cells. [Figure 13] FIG. 13 shows data on the cytotoxicity of the indicated control NK-only, T-only or NK+T constructs against target tumor cells at the first stage and upon a second re-exposure of the tumor cells. [Figure 14] Figures 14A-14B relate to studies to determine the effect of each of NK cells and T cells on the cell count of the other cell type. Figure 14A shows the results of evaluating NK cell counts when NK CAR cells are present at three different NK:Nalm6 ratios and T cells are present at the indicated ratios (X-axis). Figure 14B shows the results of evaluating T cell counts when T CAR cells are present at six different T:Nalm6 ratios and NK cells are present at the indicated ratios (X-axis). Studies were performed 7 days after co-culture of NK cells and T cells (expressing a non-limiting example of an anti-CD19 CAR (denoted 19-1)) with Nalm6 cells. [Figure 15]Figures 15A-15F show data on NK cell proliferation in the presence of T cells with chimeric antigen receptors. Figure 15A shows proliferation of NK cells (containing an anti-CD19 CAR and present at a 1:1 ratio with target Nalm6 cells) in the absence of T cells. Figure 15B shows proliferation of NK19-1 cells when T cells with the same non-limiting example CAR are present at a T:Nalm6 ratio of 1:16. Figure 15C shows proliferation of NK19-1 cells when T cells with the same non-limiting example CAR are present at a T:Nalm6 ratio of 1:8. Figure 15D shows proliferation of NK19-1 cells when T cells with the same non-limiting example CAR are present at a T:Nalm6 ratio of 1:4. Figure 15E shows proliferation of NK19-1 cells when T cells with the same non-limiting example CAR are present at a T:Nalm6 ratio of 1:2. FIG. 15F shows additional NK cell proliferation data (variable T cell numbers) at two different E:T ratios of NK cells.
[0046] [Figure 16] Figures 16A-16D show data on T cell proliferation in the presence of NK cells bearing anti-CD19 CARs. Figure 16A shows proliferation of T cells (bearing anti-CD19 CARs and present with target Nalm6 cells at a 1:2 ratio) in the absence of NK cells. Figure 16B shows proliferation of T19-1 cells in the presence of NK cells bearing the same non-limiting examples of CARs at a 1:1 NK:Nalm6 ratio. Figure 16C shows proliferation of T19-1 cells in the presence of NK cells bearing the same non-limiting examples of CARs at a 2:1 NK:Nalm6 ratio. Figure 16D shows additional T cell proliferation data (variable NK cell numbers) at various E:T ratios of NK cells. [Figure 17] Figures 17A-17C are schematic diagrams summarizing the interaction of NK cells and T cells with respect to proliferation. Figure 17A is a schematic diagram of NK cell proliferation in the presence of tumor cells alone. Figure 17B is a schematic diagram of T cell proliferation in the presence of tumor cells alone. Figure 17C shows a schematic diagram of NK cell and T cell proliferation in the presence of both tumor cells together with tumor cells. [Figure 18]Figures 18A-18L show data relating to cytokine release by mixed populations of NK and T cells. Shown are concentrations of GM-CSF (18A), IL6 (18B), IL4 (18C), IL10 (18D), IFNg (18E), IL2 (18F), TNFa (18G), IL21 (18H), IL5 (18I), IL13 (18J), IL9 (18K) and IL22 (18L).
[0047] [Figure 19] FIG. 19 is a schematic diagram of an in vivo tumor xenograft model used to evaluate the cytotoxicity of NK cells expanded according to embodiments described herein. [Figure 20] Figures 20A-20E show bioluminescence and survival data reflecting tumor burden in mice receiving the indicated treatments. Figure 20A shows animals receiving PBS (control), NK19-1 (anti-CD19 CAR expressed by NK cells), T19-1 (anti-CD19 CAR expressed by T cells) at high or low doses, and a combination of NK and T cells (at the doses shown). All groups in Figure 20A received the indicated treatments on day 3. Figure 20B shows mice receiving a combination of NK and T cells at the doses shown, with the group in the left column receiving NK cells on day 3 and T cells on day 4, and the group in the right column receiving T cells on day 3 followed by NK cells on day 4. Figures 20A-20B show data from tumor cell implantation up to day 31. Figure 20C shows data for select groups (mice surviving) from day 43 to day 121 after tumor cell implantation at the indicated timing and cell doses. Figure 20D shows the survival data for each of the experimental groups, and Figure 20E shows the survival data for selected experimental groups (among those shown in Figure 20D). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0048] Detailed Description Cancer is the abnormal proliferation of cells. There are many types of cancer and they can appear as solid tumors or as floating cells (e.g., blood cancers). Until recently, cancer treatments included chemotherapy, radiation therapy and / or surgery. More recently, cancer-specific characteristics have become clear, making cancer easier to identify, not only in diagnosis but also in the growing field of cancer immunotherapy. Cancer immunotherapy utilizes the defense mechanisms of various cells of the immune system to interact with and reduce or eliminate cancer cells. This method can be used to target and treat cancer, but also to treat other indications in which cells may be infected, such as, for example, cells infected with bacteria or viruses. In some embodiments, the immune cells are genetically engineered to be more effective against damaged or diseased tissues / cells. In some embodiments, as described in more detail herein, proliferation of immune cells is performed to increase the number of immune cells used for treatment, whether for administration to the patient in their natural form, for administration as a mixture of cells in their natural form, or for subsequent genetic engineering of the cells.
[0049] Immune Cells for Expansion and Use in Immunotherapy In some embodiments, cells of the immune system are harvested and expanded by the methods described herein, and the cells are exploited for their ability to exert a cytotoxic effect on specific target cells. In some embodiments, the harvested / expanded cells are genetically engineered to have an enhanced cytotoxic effect on target cells, such as tumor cells. In some embodiments, white blood cells (leukocytes) are used because of their inherent function of defending the body against abnormal cell proliferation and infection. There are various types of white blood cells that play specific roles in the human immune system, and thus are the preferred starting point for the engineering of cells as described herein. White blood cells include granulocytes and agranulocytes (depending on the presence or absence of granules in the cytoplasm, respectively). Granulocytes include basophils, eosinophils, neutrophils, and mast cells. Agranulocytes include lymphocytes and monocytes.
[0050] Monocytes for immunotherapy Monocytes are a subtype of white blood cells. Monocytes can differentiate into macrophages and myeloid dendritic cells. Monocytes are associated with the adaptive immune system and perform the main functions of phagocytosis, antigen presentation and cytokine production. Phagocytosis is the process of ingesting cellular material or whole cells, followed by digestion and destruction of the ingested cellular material. In some embodiments, monocytes are used in conjunction with one or more additional genetically engineered cells as described herein.
[0051] Lymphocytes for immunotherapy The other major subtype of white blood cells, lymphocytes, include T cells (cell-mediated, cytotoxic adaptive immunity), natural killer cells (cell-mediated, cytotoxic innate immunity) and B cells (humoral, antibody-driven adaptive immunity). B cells are engineered according to some aspects described herein, although some aspects also involve engineered T cells or engineered NK cells (in some embodiments, a mixture of T cells and NK cells is used).
[0052] T Cells for Immunotherapy T cells are distinguished from other lymphocyte subtypes (e.g., B cells or NK cells) based on the presence of T cell receptors on the cell surface. T cells can be classified into a wide variety of subtypes, such as effector T cells, helper T cells, cytotoxic T cells, memory T cells, regulatory T cells, natural killer T cells, mucosal-associated invariant T cells, gamma delta T cells, etc. In some embodiments, a specific subtype of T cells is engineered. In some embodiments, a mixed pool of T cell subtypes is engineered. In some embodiments, there is no specific selection of the type of T cells that are engineered to express the cytotoxic receptor complexes described herein. In some embodiments, certain techniques, such as the use of cytokine stimulation, are used to promote the expansion / collection of T cells with a particular marker profile. For example, in some embodiments, certain human T cells, e.g., CD4+ T cells, CD8 + Activation of T cells is achieved by using CD3 and / or CD28 as stimulatory molecules. In some embodiments, a method for treating or preventing cancer or infectious diseases is provided, comprising administering a therapeutically effective amount of T cells, alone or in combination with NK cells and / or other immune cells as described herein. In some embodiments, T cells are genetically engineered to enhance cytotoxicity against target cells. In some embodiments, T cells are autologous cells, while in some embodiments, T cells are allogeneic cells.
[0053] NK Cells for Immunotherapy In some embodiments, a method for treating or preventing cancer or infectious diseases is provided, comprising administering a therapeutically effective amount of NK cells, alone or in combination with T cells and / or other immune cells, as described herein. In some embodiments, the NK cells are genetically engineered to have enhanced cytotoxic effects against target cells. In some embodiments, the NK cells are autologous cells, while in some embodiments, the NK cells are allogeneic cells. In some embodiments, NK cells are preferred due to the relatively high natural cytotoxicity of NK cells. In some embodiments, it is unexpectedly beneficial that the combination of cells described herein (e.g., NK cells and T cells) synergistically interact to provide more effective activity against target cells (e.g., tumor cells or other diseased cells) compared to either NK cells alone or T cells alone.
[0054] Hematopoietic stem cells for cancer immunotherapy In some embodiments, hematopoietic stem cells (HSCs) are used in the immunotherapy described herein. In some embodiments, the cells are genetically engineered to express homing sites and / or cytotoxic receptor complexes. In some embodiments, HSCs are used to provide long-term blood cell production, taking advantage of their engraftment capacity, which can be a sustained source of targeted anti-cancer effector cells, for example, to combat cancer remission. In some embodiments, this continued production helps to counteract allergies or exhaustion of other cell types, for example, due to the tumor microenvironment. In some embodiments, allogeneic hematopoietic stem cells are used, while in some embodiments, autologous hematopoietic stem cells are used. In some embodiments, HSCs are used in combination with one or more additional immune cell types described herein.
[0055] Feeder cells for immune cell expansion In some embodiments, there is provided the use of feeder cell populations (either clonal or mixed populations) that function to expand both NK cells and T cells from a blood sample of a donor (which in some embodiments can also be a patient).
[0056] In some embodiments, the cell line is used in co-culture with the population of immune cells to be expanded. Such cell lines are referred to herein as "stimulator cells" or "feeder cells." In some embodiments, the entire population of immune cells should be expanded, while in some embodiments, a subpopulation or subpopulations of selected immune cells are preferentially expanded. For example, in some embodiments, NK cells are preferentially expanded over other immune cell subpopulations. In some embodiments, two or more subpopulations are expanded together, in some embodiments simultaneously. In some embodiments, as described in more detail below, two or more subpopulations need not be expanded to the same extent as each other. Rather, in some embodiments, one subpopulation can be expanded more or less than the other subpopulation to obtain the desired ratio of population 1 to population 2 at the end of the expansion period.
[0057] In some embodiments, the feeder cells are wild-type cells, while in some embodiments, the feeder cells are genetically modified to be particularly suitable for the proliferation and / or activation of immune cells, especially in the presence of one or more additional stimulatory signals. As described in detail below, various cell lines have been adapted for genetic modification that can result in the surface expression of specific molecules that stimulate NK activation. Certain cell types, such as those with low, limited, or otherwise absent expression of major histocompatibility complex (MHC) I molecules, are particularly useful for the co-expansion of NK cells and T cells (and / or other mononuclear cells, depending on the embodiment, as desired), since MHC I molecules have an inhibitory effect on NK cells. In some embodiments, K562 cells are used, while in some embodiments, K562 cells, Wilms' tumor cell line HFWT, endometrial tumor cell line HHUA, melanoma cell line HMV-II, hepatoblastoma cell line HuH-6, small cell lung carcinoma cell lines Lu-130 or Lu-134-A, neuroblastoma cell lines NB19 or NB69, embryonal carcinoma testicular cell line NEC14, cervical carcinoma cell line TCO-2, and neuroblastoma cell line TNB1 are used.
[0058] In some embodiments, the cells do not need to completely lack MHC I expression, but may express MHC I molecules at a lower level than wild-type cells. For example, in some embodiments, if wild-type cells express MHC at a level of X, the cell line used may express MHC at an expression level of less than 95% of X, less than 90% of X, less than 85% of X, less than 80% of X, less than 70% of X, less than 50% of X, less than 25% of X, and any value between (and including). In some embodiments, the stimulator cells are immortalized, e.g., cancer cell lines. However, in some embodiments, the stimulator cells are primary cells. In some embodiments, the feeder cells are also cells with reduced (or deleted) MHC II expression. In some embodiments, other cell lines (or clonal lines) that can express MHC class I molecules can be used in conjunction with genetic modification of those cells to reduce or knock out MHC I expression. Such genetic modifications can be achieved by using various gene editing techniques (e.g., the CRISPR / Cas-9 system), inhibitory RNA (e.g., siRNA), or other molecular methods to prevent and / or reduce expression of MHC I molecules, in addition to blocking antibodies, interfering ligands (e.g., competitive inhibitors, non-competitive inhibitors, etc.).
[0059] As described in more detail below, specific stimulatory molecules are optionally engineered to be expressed by the feeder cells, and such stimulatory molecules act to promote the proliferation and / or activation of immune cells. In some embodiments, the stimulatory molecules can be expressed by the feeder cells, but can also be provided separately. In some embodiments, the stimulatory molecules can be added directly to the culture medium, which has the advantage that their concentration can be easily assessed and replenished. In some embodiments, the molecules are provided immobilized or otherwise bound to additives such as metals, glass, plastics, polymeric materials, particles (e.g., beads or microspheres), and / or lipids (either natural or synthetic), or any other material to which the stimulatory molecules can be bound.
[0060] Certain molecules promote the proliferation, survival and / or activation of immune cells, and in some embodiments, promote the proliferation, survival and / or activation of certain subpopulations of immune cells. Depending on the embodiment, the stimulatory molecule or molecules can be expressed on the surface of feeder cells used to expand the immune population (or populations). In further embodiments, one or more stimulatory molecules are used to supplement the cell culture medium, either directly or attached to any additive (e.g., beads). In some embodiments, the immune cell population is expanded relatively uniformly (e.g., no particular subpopulation is preferentially expanded). However, in some embodiments, two or more subpopulations are expanded. Depending on the embodiment, the two subpopulations may or may not be expanded to the same extent as each other. In some embodiments, they may be expanded to the same or similar relative extent, but with respect to the absolute number of cells in the resulting expanded immune cell population, the number differs, at least in part, based on the different starting number of cells of each of the two subpopulations. In some such embodiments, if desired, before or after expansion of all immune cell populations, the desired subpopulations are selectively separated for further use (e.g., NK cells are separated from T cells, or vice versa).
[0061] In some embodiments, interleukin 15 (IL15) is used to promote the proliferation of immune cells such as NK cells. In some embodiments, IL15 is membrane bound on the feeder cells (referred to herein as "mbIL15"). In some embodiments, IL15 is membrane bound by being bound or complexed to a transmembrane molecule or an integral membrane protein. In some embodiments, the transmembrane domain of CD8α is used. In some embodiments, wild-type (e.g., full-length) IL15 is expressed on or by the feeder cells. In some embodiments, IL15 has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% homology to full-length IL15. In some embodiments, a truncated form of IL15 is used. Further details about this and other constructs related to the proliferation of immune cells are described in PCT Application No. PCT / SG2018 / 050138, filed March 27, 2018, the entire contents of which are incorporated herein by reference.
[0062] In some embodiments, 4-1BB ligand (4-1BBL) is used to promote the proliferation of immune cells. 4-1BBL has an extracellular domain that interacts with its receptor, 4-1BB, on T cells, thereby providing T cells with costimulatory signals for survival, proliferation and differentiation. In some embodiments, 4-1BBL is membrane-bound on the feeder cells by being bound or complexed to a transmembrane molecule or an integral membrane protein. In some embodiments, wild-type (e.g., full-length) 4-1BBL is expressed on or by the feeder cells. In some embodiments, 4-1BBL has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% homology to full-length 4-1BBL. In some embodiments, truncated forms of 4-1BBL are used. In some embodiments, 4-1BBL is expressed or provided to the culture in a manner other than by expression on the feeder cells. In some embodiments, 4-1BBL is expressed on the surface of feeder cells (including by a clonal population of feeder cells) in combination with mbIL-15. In some embodiments, this combination of stimulatory signals provides a stimulus to induce proliferation of NK cells in a starting sample of immune cells or peripheral blood mononuclear cells.
[0063] As described herein, in some embodiments, supplemental growth stimuli are also provided that function to further enhance the proliferation of one or more subpopulations of immune cells. For example, in some embodiments, supplemental stimuli are provided that enhance the proliferation and expansion of NK cells. In some embodiments, the supplemental stimuli function to enhance the proliferation of T cells (while another stimulatory molecule or molecules induce the proliferation of NK cells). In some embodiments, the supplemental stimuli can be achieved by a single additional stimulatory molecule. However, in some embodiments, the supplemental stimuli are provided by two or more stimulatory molecules that act in concert with each other.
[0064] For example, in some embodiments, one or more cytokines are added to the medium in which the NK cells and T cells are cultured. In some embodiments, IL12, IL18 or IL21 (or a combination thereof) are added. In some embodiments, the cytokine(s) are added by genetically engineering the feeder cells to express the cytokine(s). In some embodiments, membrane-bound cytokines are used, and in other embodiments, feeder cells designed to express soluble cytokines are used. In some embodiments, one or more soluble cytokines are added to the culture at the beginning of the expansion of the NK cells and T cells, or at various times during.
[0065] In some embodiments, the anti-CD3 antibody is used to promote the proliferation of immune cells. In some embodiments, the anti-CD3 antibody is membrane-bound to the feeder cells. In some embodiments, the full-length anti-CD3 antibody is expressed on the feeder cells. However, in some embodiments, the anti-CD3 antibody comprises a single-chain fragment variable region (scFv) fragment. Depending on the embodiment, the antibody can be monoclonal or polyclonal. In some embodiments, the anti-CD3 antibody comprises various antigenic fragments and / or fusions selected from Fab', F(ab')2, single domain antibodies (e.g., bispecific antibodies, nanobodies). In some embodiments, the antibody is selected from the group consisting of muromonab-CD3, otelixizumab, teplizumab and vicilizumab, or an antibody (or fragment) having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% homology (or functional equivalence) with one or more of muromonab-CD3, otelixizumab, teplizumab and vicilizumab. In some embodiments, the anti-CD3 antibody is provided in association with an additional material that is added to the culture medium when the feeder cells are co-cultured with the immune cells to be expanded. In some embodiments, the additional material is provided on the surface or via secretion in addition to the expression of the anti-CD3 antibody by the feeder cells.
[0066] In some embodiments, the anti-CD28 antibody is used to promote the proliferation of immune cells. In some embodiments, the anti-CD28 antibody is membrane-bound on the feeder cells. In some embodiments, the full-length anti-CD28 antibody is expressed on the feeder cells. However, in some embodiments, the anti-CD28 antibody comprises a single-chain fragment variable region (scFv) fragment. In some embodiments, the antibody is monoclonal or polyclonal. In some embodiments, the anti-CD28 antibody comprises various antigenic fragments and / or fusions selected from Fab', F(ab')2, single domain antibodies (e.g., bispecific antibodies, nanobodies). In some embodiments, the antibody is selected from the group consisting of ceralizumab and antibodies (or fragments) having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% homology (or functional equivalence) with one or more of ceralizumab. In some embodiments, the anti-CD28 antibody is provided attached to additional materials that are added to the culture medium when the feeder cells are co-cultured with the immune cells to be expanded. In some embodiments, this additional material is provided on the surface or via secretion in addition to expression of the anti-CD28 antibody by the feeder cells.
[0067] In some embodiments, anti-CD3 and anti-CD28 antibodies are provided together to synergistically enhance T cell proliferation. In some embodiments, anti-CD3 and anti-CD28 antibodies are provided bound to a solid support or other additional material, such as beads or other geometric shapes. In some embodiments, a population of beads has a portion bound to anti-CD3 antibody and another portion bound to anti-CD28 antibody, while in some embodiments, the antibodies are both present on the beads (or other material).
[0068] Depending on the embodiment and depending on the stimulatory molecule(s) of interest, the stimulatory molecule may be introduced (e.g., added to the culture or expressed by feeder cells) at a particular time point during the course of co-culture with the immune cell population, or multiple immune cell subpopulations. For example, rather than being constitutively expressed during co-culture, one or more stimulatory molecules may be under the control of an inducible or otherwise controllable promoter. In this manner, a triggering molecule or stimuli may be added to the co-culture at the desired time point to cause expression of the desired stimulatory molecule(s) at a particular time point in the expansion and activation protocol. For example, in some embodiments, it may be desirable to preferentially expand NK cells first, followed by T cells. Thus, at early stages of expansion, molecules that stimulate NK cells may be "turned on," and at later stages, molecules that stimulate T cells may be "turned on." As noted above, "on" may be the result of regulated expression of the stimulatory molecule, or may simply be the result of addition of the stimulatory molecule to the culture. As used herein, the terms "inducible promoter" and "regulatable promoter" shall be given their ordinary meaning and shall mean a promoter whose transcriptional activity is regulated (e.g., stimulated or inhibited) by the presence of a particular biological or non-biological factor. As used herein, the term "trigger molecule" or "trigger stimulus" shall be used in its ordinary sense and shall mean a chemical or physical substance or condition that acts on an inducible or regulatable promoter, such as alcohol, tetracycline, steroids, metals and other compounds, and high or low culture temperatures. Additionally, regulatable expression of stimulatory molecules may be utilized to reduce and / or eliminate expression of particular stimulatory molecules during the culture process. Such embodiments may promote preferential proliferation of particular subpopulations of immune cells, such as NK cells, for example, by providing a particular stimulatory signal at a point during the activation and proliferation process where NK cells are particularly sensitive to such signaling. In some embodiments, such an approach may result in unexpectedly robust activation and proliferation of NK cells.In yet additional embodiments, the NK cell expansion period is extended, ultimately resulting in a larger population of activated NK cells for use in, for example, cancer immunotherapy. Similarly, in some embodiments, another signal can be provided to expand a second (or further) desired subpopulation of immune cells, such as T cells. As a result, in some embodiments, the resulting expanded cell population can include a mixture of NK cells and T cells that have been expanded to a degree that differs from the relative amount of NK:T cells present in the donor.
[0069] In some embodiments, within a given population of feeder cells, certain individual cells within the population are particularly suitable for expanding two or more desired immune cells, such as expanding both NK cells and T cells simultaneously. Identification of such individuals (e.g., clones) is described in more detail below. In some embodiments, the identified clones are replicated to provide a clonal population of feeder cells, each individual sharing the beneficial properties of the original parent cell with respect to the ability to simultaneously expand two or more types of immune cells, such as NK cells and T cells. Thus, in some embodiments, a clonal population of feeder cells is used to expand one or more subpopulations of immune cells together, optionally simultaneously (e.g., NK cells and T cells).
[0070] Donor Material and Processing In some embodiments, methods for expanding multiple populations of immune cells are particularly advantageous as they provide sufficient flexibility to account for variations in donor cell populations. As shown in Figures 1A to 1D, the relative distribution of NK cells and T cells relative to other cells in baseline blood samples can vary considerably. In normal peripheral blood, the relative abundance of T cells ranges from about 10 to about 25%, while the abundance of normal T cells ranges from about 2 to about 5% (see, e.g., https: / / www.bio-rad-antibodies.com / static / 2017 / flow / flow-cytometry-cell-frequency.pdf). Figure 1A shows those percentages from Donor 1, which is about 12.5% T cells, about 12.5% NK cells, and the remaining about 75% composed of other cell types. Donor 2, shown in Figure 1B, had about 35% T cells and only about 5% NK cells. Donor 3, shown in Figure 1C, had about 20% T cells and about 10% NK cells. Similarly, donor 4, shown in Figure 1D, had approximately 25% T cells and 5% NK cells. These sample data show that donor-to-donor variability can be substantial, sometimes falling outside the “normal” expected ranges for NK and T cells.
[0071] As can be seen from the data above, in some embodiments, the culture method or process can be adjusted to accommodate this variation in the starting material. For example, in some embodiments, the methods and processes described herein can achieve a desired NK:T cell ratio even when starting with substantially different initial NK in T cell populations. In some embodiments, the percentage of NK cells provided as starting material can range from about 0.5% to about 35% of peripheral blood mononuclear cells of a blood sample, including about 0.5% to about 1%, about 1% to about 2%, about 2% to about 4%, about 3% to about 5%, about 2% to about 5%, about 5% to about 10%, about 10% to about 15%, about 15% to about 20%, about 20% to about 25%, about 25% to about 30%, about 30% to about 35%, and any percentage of NK cells in the starting sample between the values (including the endpoints) explicitly stated. In some embodiments, the percentage of NK cells in the starting sample ranges from about 2% to about 5%. Similarly, the percentage of T cells present in the blood sample may vary. For example, in some embodiments, the percentage of T cells provided in the starting sample ranges from about 5% to about 30%, including about 5% to about 10%, about 10% to about 15%, about 15% to about 20%, about 20% to about 25%, about 25% to about 30%, and any percentage of T cells in the starting sample between the values (including the endpoints) explicitly stated.
[0072] In some embodiments, the significant degree of proliferation that occurs during the implementation of the methods and processes described herein minimizes the impact of starting material variability on the final mixed cell population.In other words, in some embodiments, cell populations are expanded to a significant degree so that the resulting number of NK cells, T cells and / or other desired immune cell subpopulations is clinically relevant, even though the absolute number of cells may differ compared to each other.
[0073] As described in more detail below, advantageously, despite potentially substantial differences in the relative abundance of NK cells versus T cells in the starting blood sample, the methods and processes described herein allow for the coordinated expansion of both cell types (including, optionally, adjustable additional immune cell subpopulations) to achieve a desired ratio in the final mixed population of NK cells and T cells. For example, in some embodiments, the ratio of NK cells to T cells in the ultimate mixed population of cells can range from about 100:1 to about 1:100, depending on the embodiment.
[0074] Complex proliferation of immune cells As described above, in some embodiments, multiple subpopulations of immune cells are expanded in culture together. Depending on the embodiment, a single expansion protocol may be used to expand multiple cell populations sequentially (e.g., first expanding NK cells, followed by expanding T cells) or in parallel (e.g., simultaneous co-culture of NK cells and T cells). A single expansion protocol according to some embodiments may include multiple expansion phases directed to preferentially expand one cell type over the other, even when, for example, both NK cells and T cells are present in the culture at the same time.
[0075] As described above, various types of feeder cells can be used to induce the proliferation of multiple types of desired immune cells. The feeder cells used may, in some embodiments, be composed of a mixed population of feeder cells, including a population of feeder cells that have an overall stimulatory growth-promoting effect, but where individual cells within the population potentially have different properties compared to other members of the feeder cell population. However, in some embodiments, feeder cells with desirable properties for stimulating the proliferation of multiple immune cell subpopulations are identified and clonally expanded, and the resulting clonal population of feeder cells is used for the combined proliferation of multiple immune cell types. In some embodiments, two, three, four (or more) types of immune cells can be co-expanded. In some embodiments, the co-expanded immune cells are two or more of NK cells, cytotoxic T cells, natural killer T cells (NKT cells), effector T cells, helper T cells, memory T cells, regulatory T cells, gamma delta T cells, mucosal-associated invariant T cells, and / or various types of NK cell subpopulations (e.g., NK cells with stronger activating receptor signaling compared to inhibitory receptor signaling, or vice versa). A non-limiting embodiment of an approach for co-growth is depicted diagrammatically in FIG. 2 and explained in more detail in the Examples below.
[0076] Depending on the embodiment, feeder cells (either a mixed or clonal population) are seeded into the culture vessel. The seeding density varies depending on the embodiment, for example, about 0.5×10 5 cells / cm 2 ~Approx. 5×10 7 cells / cm 2 This range is about 1.0 × 10 5 cells / cm 2 ~Approx. 1.5×10 5 cells / cm 2 , about 1.5×10 5 cells / cm 2 ~Approx. 5×10 5 cells / cm 2 , about 5×10 5 cells / cm 2 ~Approx. 1.0×106 cells / cm 2 , about 1.0×10 6 cells / cm 2 ~Approx. 5×10 6 cells / cm 2 , about 5×10 6 cells / cm 2 ~Approx. 1.0×10 7 cells / cm 2 , about 1.0×10 7 cells / cm 2 ~Approx. 5.0×10 7 cells / cm 2 , 1 cm , 2 cm , 3 cm , 4 cm , 5 cm , 6 cm , 7 cm , 8 cm , 9 cm , 10 cm , 11 cm , 12 cm , 13 cm , 14 cm , 15 cm , 16 cm , 17 cm , 18 cm , 20 cm , 25 cm , 26 cm , 27 cm , 28 cm , 30 cm , 31 cm , 32 cm , 33 cm , 34 cm , 35 cm , 36 cm , 37 cm , 38 cm , 39 cm , 40 cm , 41 cm , 42 cm , 43 cm , 44 cm , 45 cm , 46 cm , 47 cm , 48 cm , 50 cm , 51 cm 2 Approximately 1 x 10 6 An initial seeding density of cells is used.
[0077] In some embodiments, feeder cells may be pretreated with one or more agents to reduce the proliferation rate of the feeder cells themselves.For example, in some embodiments, feeder cells are irradiated before being cultured with the immune cell population to be expanded.In some embodiments, instead of or as a supplement to irradiation, feeder cells are treated with anti-proliferative agents, such as mitomycin C.
[0078] As mentioned above, in some embodiments, a particular individual cell within a larger population of feeder cells has desirable properties for the expansion of two or more immune cell subtypes. In some embodiments, the feeder cells used to expand immune cell populations are clonally derived populations of feeder cells. In other words, individual clones identified as having desirable properties for the expansion of one or more types of immune cells are themselves clonally expanded, so that the resulting populations all share those beneficial properties. In some embodiments, exposing the immune cells to be expanded to a clonal population of feeder cells can advantageously reduce the variability of the final expanded immune cell population. As a result, in some embodiments, greater product consistency is achieved.
[0079] Also, as mentioned above, in some embodiments, the growth medium can be supplemented with one or more stimulatory molecules. In some embodiments, such molecules promote the general health of the feeder cell layer, stimulate the immune cell population being expanded, enhance the health of the immune cell population before, during or after expansion, or some combination of these functions. In some embodiments, interleukin-2 (IL2) is used to supplement the medium. In some embodiments, the concentration of interleukin-2 can be varied over the period during which the immune cell expansion is performed. The IL2 concentration can be in the range of about 10 units / mL to about 20 units / mL, about 20 units / mL to about 40 units / mL, about 40 units / mL to about 60 units / mL, about 60 units / mL to about 80 units / mL, about 80 units / mL to about 100 units / mL, about 100 units / mL to about 150 units / mL, about 150 units / mL to about 200 units / mL, about 200 units / mL to about 300 units / mL, about 300 units / mL to about 400 units / mL, about 400 units / mL to about 500 units / mL, about 500 units / mL to about 750 units / mL, about 750 units / mL to about 1000 units / mL, and any concentration therebetween (including endpoints). Stimulation with IL-2 can be repeated multiple times per proliferation protocol according to certain embodiments. Additionally, restimulation can be performed, as well as stimulation at various concentrations can be performed at different times during the expansion protocol. In some embodiments, other interleukins or other stimulatory molecules can be used in the processes described herein.
[0080] In some embodiments, the expansion period of the cells ranges from about 4 days to about 20 days. In some embodiments, different immune cell subpopulations expand at different rates depending on the duration of culture with feeder cells. For example, certain cell types expand more rapidly at earlier time points and other cell types expand more rapidly at later time points. Thus, if a different proportion of immune cell subtypes in the final immune cell population is desired, the timing of expansion can be adjusted accordingly. In some embodiments, expansion conditions are employed for about 4-6 days, about 6-8 days, about 8-10 days, about 10-14 days, or about 14-21 days. In some embodiments, the overall absolute number of expanded cells can be increased by increasing the expansion culture time. However, in some embodiments, the expansion time can be adjusted to be decreased by performing a preliminary enrichment step to ensure that the starting number of each expanded immune cell subtype is greater than that in the original collected sample.
[0081] In some embodiments, the ratio of feeder cells to the immune cells to be expanded can be adjusted depending on the final desired result and the composition of the immune cell population to be expanded. For example, in some embodiments, a ratio of feeder cells:"target" cells of about 5:1 is used. In some embodiments, a ratio of 1:1 is used, and in further embodiments, the ratio can include about 1:10, 1:20, 1:50, 1:100, 1:1,000, 1:10,000, 1:50,000, 1:100,000, 100,000:1, 50,000:1, 10,000:1, 1,000:1, 100:1, 50:1, 20:1, 10:1, and all ratio ranges and endpoints therebetween. In some embodiments, a combination of cell types (e.g., a combination of K562 with one or more additional cell types) is used, such that activation and / or expansion of NK cells is greater than can be achieved using any single cell type alone (e.g., as a result of synergy between the cell types). In some such embodiments, expression of MHC I does not necessarily need to be reduced and / or deleted in each of the cell lines used in combination. In some embodiments, the relative frequency of one cell type and the other cell type in the combination can be varied to maximize the expansion and activation of the desired immune cell population. For example, when two feeder cell populations are used, the relative frequencies can be 1:10, 1:20, 1:50, 1:100, 1:1,000, 1:10,000, 1:50,000, 1:100,000, 100,000:1, 50,000:1, 10,000:1, 1,000:1, 100:1, 50:1, 20:1, 10:1, and all ratio ranges and endpoints therebetween listed.
[0082] Similarly, given that multiple immune cell subpopulations are expanded in combination according to some embodiments described herein, the initial ratio of immune cell subtypes to each other can be adjusted in certain embodiments. For example, as described above, there may be donor-to-donor variability in the relative abundance of NK cells to T cells in a given blood sample. Thus, in some embodiments, if one cell type is in relative excess compared to the other in a particular sample, an enrichment or depletion step can be performed to achieve a desired input ratio of cell type 1 to cell type 2. For example, and as a non-limiting example, consider a blood sample drawn from a donor in which T cells make up about 25% of the collected cell population and NK cells make up about 5% of the collected cell population. In such embodiments, a preliminary expansion step can be used to increase the number of NK cells so that the absolute number of NK cells is approximately equal to the absolute number of T cells from the collected blood sample. With equal numbers of NK cells and T cells, the NK cells and T cells can then be cultured with feeder cells to induce expansion and ultimately achieve a desired ratio of NK cells to T cells in the expanded cell population, e.g., 1:1. In another approach, a large population of T cells can be depleted to reduce the number of T cells to an amount roughly equivalent to the number of NK cells, and then equal numbers of NK and T cells can be co-cultured with feeder cells as described herein.
[0083] Similar to adjusting the ratio of feeder cells to immune cells to be expanded, the relative ratios of different types of immune cells to be expanded within a given culture can be adjusted. For example, the ratio of NK cells to T cells at the initial stage of a given culture can be adjusted to about 10,000:1, about 7500:1, about 5000:1, about 2500:1, about 2000:1, about 1500:1, about 1000:1, about 750:1, about 500:1, about 250:1, about 100:1, about 75:10, about 50:1, about 25:1, about 15:1, about 10:1, about 5:1, about 1:1, about 1:5, about 1:10, about The range can be from about 10,000:1 to about 1:10,000 cells, including 1:25, about 1:50, about 1:75, about 1:100, about 1:250, about 1:500, about 1:750, about 1:1000, about 1:1500, about 1:2000, about 1:2500, about 1:5000, about 1:7500, about 1:10,000, and all ratios and endpoints in between.
[0084] As described in more detail below, in some embodiments, supplemental stimuli are used that are intended to induce preferential proliferation of one of the multiple types of immune cells that are cultured in combination with other types of immune cells as well as feeder cells. In some embodiments, the supplemental stimuli are added at the beginning of the proliferation phase and can essentially be considered part of the original stimulatory environment. In further embodiments, the introduction of the supplemental stimuli can be delayed, for example, to allow a first phase proliferation of a particular cell type to be followed by a second phase proliferation of a different cell type, the latter induced by the introduction of the supplemental stimuli. In some embodiments, the supplemental stimuli can be administered about 3 days, about 4 days, about 5 days, about 7 days, about 10 days, about 14 days, or any time therebetween after the initiation of co-culture. In other words, the supplemental stimulus can be added after about 0% of the expansion protocol is complete, after about 10% of the expansion protocol is complete, after about 25% of the expansion protocol is complete, after about 50% of the expansion protocol is complete, or after about 75% of the expansion protocol is complete.
[0085] In some embodiments, as described in more detail below, it is not necessary for two or more subpopulations to be expanded to the same extent as one another. Rather, in some embodiments, one subpopulation can be expanded more or less than the other subpopulations to obtain a desired ratio of population 1 to population 2 at the end of the expansion period. The desired ratio after expansion can be, for example, about 10,000:1, about 7500:1, about 5000:1, about 2500:1, about 2000:1, about 1500:1, about 1000:1, about 750:1, about 500:1, about 250:1, about 100:1, about 75:10, about 50:1, about 25:1, about 15:1, about 10:1, about 5:1, about 1:1, about 1:5, about 1:10, about 1:25, about 1:50, about The ratio of NK cells to T cells may range from about 10,000:1 to about 1:10,000 cells, including 1:75, about 1:100, about 1:250, about 1:500, about 1:750, about 1:1000, about 1:1500, about 1:2000, about 1:2500, about 1:5000, about 1:7500, about 1:10,000, and all ratios and endpoints in between.
[0086] Genetic manipulation of expanded cells In some embodiments, the expanded immune cells can be administered to a subject in need of immunotherapy without further modification. In some embodiments, the expanded immune cell population is mixed with a pharma- ceutically acceptable carrier and then administered. As detailed below, administration can be by any of a variety of routes and can be in an autologous or allogeneic context. In some embodiments, the expanded cells are genetically engineered to enhance cytotoxic effects against target tumor cells. For example, NK cells and / or T cells can be genetically engineered to express chimeric receptors that enhance the ability of the NK cells and / or T cells to recognize, for example, tumor cells and / or exert a cytotoxic effect. The cells can be genetically engineered in a variety of different ways, including those described in detail in PCT Patent Application No. PCT / US2018 / 024650, filed March 27, 2018, the entire contents of which are incorporated herein by reference.
[0087] Cytotoxicity Receptor Complex Various cytotoxic receptors may be expressed by the NK / T cells described herein. In some embodiments, the receptor comprises a chimeric antigen receptor (CAR). In some embodiments, the CAR is directed against one or more of the target tumor markers described herein. In some embodiments, the CAR is encoded by a specific polynucleotide encoding an amino acid sequence. In some embodiments, a polynucleotide is provided that encodes an anti-CD19 moiety / CD8 hinge / CD8TM / OX40 / CD3ζ chimeric antigen receptor complex. The polynucleotide comprises or consists of an anti-CD19 scFv, a CD8a hinge, a CD8a transmembrane domain, an OX40 domain, and a CD3ζ domain. In some embodiments, the chimeric antigen receptor further comprises mbIL15. In such embodiments, the polynucleotide comprises or consists of an anti-CD19 scFv, a CD8a hinge, a CD8a transmembrane domain, an OX40 domain, a CD3zeta domain, a 2A cleavage site, and a mbIL-15 domain, as described herein. In some embodiments, the receptor complex is encoded by a nucleic acid molecule having the sequence of SEQ ID NO:1. In some embodiments, the nucleic acid sequence encoding the NK19 chimeric antigen receptor comprises a sequence having at least about 90%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity, homology, and / or functional equivalence to SEQ ID NO:1. In some embodiments, the chimeric receptor comprises the amino acid sequence of SEQ ID NO:2. In some embodiments, the NK19 chimeric antigen receptor comprises an amino acid sequence having at least about 90%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% sequence identity, homology, and / or functional equivalence to SEQ ID NO:2. In some embodiments, the CD19 scFv does not comprise a Flag tag. In some embodiments, a humanized and / or codon-optimized CAR is used.Further examples of tumor-binding constructs that may be used in accordance with the embodiments described herein are described in PCT Patent Application No. PCT / US2018 / 024650, filed March 27, 2018, U.S. Provisional Patent Application No. 62 / 814,180, filed March 5, 2019, U.S. Provisional Patent Application No. 62 / 895,910, filed September 4, 2019, U.S. Provisional Patent Application No. 62 / 932,165, filed November 7, 2019, and U.S. Provisional Patent Application No. 62 / 924,967, filed October 23, 2019, the contents of each of which are incorporated herein by reference in their entirety.
[0088] Administration and Dosage Further provided herein is a method for treating a subject with cancer, comprising administering to the subject a composition comprising a mixed population of expanded immune cells (e.g., a mixture of NK cells and T cells).In some embodiments, the expanded cells are genetically engineered to express a cytotoxic receptor complex (e.g., a chimeric receptor or a chimeric antigen receptor).The use of such genetically modified immune cells for treating cancer is also provided. In certain embodiments, treatment of a subject with an expanded mixed cell population described herein achieves, for example, one, two, three, four or more of the following effects: (i) reduction or amelioration of the severity of a disease or a symptom associated therewith, (ii) reduction in the duration of a symptom associated with a disease, (iii) protection against progression of a disease or a symptom associated therewith, (iv) regression of a disease or a symptom associated therewith, (v) protection against the onset or onset of a symptom associated with a disease, (vi) protection against recurrence of a symptom associated with a disease, (vii) reduction in hospitalization of the subject, (viii) reduction in the length of hospitalization, (ix) increase in the survival time of a subject with a disease, (x) reduction in the number of symptoms associated with a disease, (xi) enhancement, improvement, complement, supplement or augmentation of the prophylactic or therapeutic effect of another therapy, (xii) a biphasic (e.g., immediate and long-lasting) cytotoxic effect on a target cell. Each of these comparisons is, for example, to a different therapy for a disease, including cell-based immunotherapy for a disease using cells that do not express a construct described herein.
[0089] Administration can be by a variety of routes, including, but not limited to, intravenous, intraarterial, subcutaneous, intramuscular, intrahepatic, intraperitoneal, and / or localized delivery to the affected tissue. The dosage of the expanded mixed population of immune cells can be readily determined for a given subject based on the subject's weight, the type and condition of the disease, and the desired aggressiveness of the treatment, but in some embodiments, can be about 10 mg / kg. 5 Approximately 10 per kg of cells 12 A range of cells (e.g., 10 5 -10 7 , 10 7 -10 10 , 10 10 -10 12 and overlapping ranges therein). In some embodiments, the mixed population of immune cells has an engineered ratio of various cell types. For example, in a mixed population of NK cells and T cells, the ratio of NK:T cells can be in the range of about 1000:1, about 750:1, about 500:1, about 250:1, about 100:1, about 75:1, about 50:1, about 25:1, about 10:1, about 5:1, about 2:1, about 1:1, about 1:2, about 1:5, about 1:10, about 1:25, about 1:50, about 1:75, about 1:100, about 1:250, about 1:500, about 1:750, or about 1:1000 (or any ratio therebetween as listed). In some embodiments, the ratio of NK cells to T cells is expressed in terms of target cell number. For example, in some embodiments, the ratio of NK:target cells is about 1:1, 1:2, 1:4, 1:8, or 1:10, and the ratio of T cells:target cells is about 1:2, 1:4, 1:8, or 1:10. In some embodiments, a combination of these ratios is used, e.g., NK cells:target cells are 1:4 and T cells:target cells are 1:8.
[0090] Similarly, in some embodiments, three (or more) different types or subtypes of cells can be used in a mixed population, where the ratios can range from about 1:1:1, where the three subtypes of cells are roughly equivalent to each other, to about 1000:1:1 or about 1:1:1000, where one cell type predominates over the other. Similarly, intermediate ratios can be used depending on the embodiment, such as about 10:5:1, or about 1:5:10, or about 5:1:10 ratios. Furthermore, subpopulations can be combined in a range of ratios with each other. For example, when a population is composed of two cell types, a predetermined parameter can be used to determine the population size of the first cell type, which can then be used to determine the population size of the second (or third, fourth, etc.) cell type. As a non-limiting example, the cytotoxicity of NK cells against a target cell population can be calculated to determine the number of NK cells to be added to the population, which is used as an input for a subsequent calculation to calculate the number of T cells to be added to the population. When a highly effective population of NK cells is used, the NK cells may comprise, for example, 25% of the mixed population, with gamma delta T cells making up the remainder (or less if a third or fourth cell type is added).
[0091] In some embodiments, a dose escalation regimen is also provided. In some embodiments, for example, about 1×10 6 Cells / kg to approximately 1 x 10 8Immune cells (e.g., NK cells and T cells) ranging between 1000 and 10000 cells / kg are administered. Depending on the embodiment, various types of cancer can be treated. In some embodiments, hepatocellular carcinoma is treated. Further embodiments provided herein include the treatment or prevention of the following non-limiting examples of cancer, including acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), adrenocortical carcinoma, Kaposi's sarcoma, lymphoma, gastrointestinal cancer, appendix cancer, central nervous system cancer, basal cell carcinoma, bile duct cancer, bladder cancer, bone tumor, brain tumor (including but not limited to astrocytoma, spinal tumor, brain stem glioma, glioblastoma, craniopharyngioma, ependymoblastoma, ependymoma, medulloblastoma, medulloepithelioma), breast cancer, bronchial tumor, Burkitt's lymphoma, and the like. Cancers of the present invention include, but are not limited to, breast cancer, cervical cancer, colon cancer, chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), chronic myeloproliferative disorders, ductal carcinoma, endometrial cancer, esophageal cancer, gastric cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell leukemia, renal cell carcinoma, leukemia, oral cancer, nasopharyngeal cancer, liver cancer, lung cancer (including but not limited to non-small cell lung cancer (NSCLC) and small cell lung cancer), pancreatic cancer, intestinal cancer, lymphoma, melanoma, eye cancer, ovarian cancer, pancreatic cancer, prostate cancer, pituitary cancer, uterine cancer, and vaginal cancer.
[0092] As discussed in more detail herein, various genetically modified cells can be used to target a number of different tumor types. Depending on the embodiment, solid or floating tumors can be targeted. In some embodiments, the genetically modified cells described herein are used to treat hematological tumors. For example, in some embodiments, acute myeloid leukemia (AML) is treated with the genetically modified cells described herein. ) cells are targeted. AML results from the clonal proliferation of blasts in the bone marrow, blood or other tissues. AML accounts for approximately 3% of all cancers, and the incidence of AML increases with age. In patients 65 years of age or younger, approximately 70-80% of patients achieve complete remission, with an overall survival rate of approximately 35%. In patients 65 years of age or older, the numbers decrease, with remission in 40-60% of cases and an overall survival rate of approximately 5%. Shown in the immunohistochemistry panel in Figure 2 is a bone marrow aspirate that stained positive for leukemic blasts.
[0093] The genetically modified cells described herein can be used to target various markers. CD19, CD123, NY-ESO, BCMA, etc. are expressed in many cancers. In some embodiments, CD123 and NKG2D ligands are upregulated, especially in AML. In certain patients (e.g., AML patients), the surface expression of NKG2D ligands (including but not limited to MICA, MICB, ULPB1, ULPB2, ULPB3) is upregulated. Similarly, in some of these patients, a significant proportion (e.g., about 80% or more) of blast cells, leukemia stem cells and endothelial cells are CD123 positive. Thus, in some embodiments, immune cells are genetically engineered to target NKG2D ligands and / or CD123.
[0094] The following list includes non-limiting examples of antigens that can be bound by the binding / activation sites described herein: Her2, prostate stem cell antigen (PSCA), alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), CD123, CD19, claudin 6, NY-ESO, GD-2, GD-3, dectin-1, cancer antigen-125 (CA-125), CA19-9, calretinin, MUC-1, epithelial membrane protein (EMA), epithelial tumor antigen (ETA), tyrosinase, melanoma associated antigen (MAGE), CD34, CD45, CD99, CD117, chromogranin, cytokeratin, desmin, glial fibrillary acidic protein (GFAP), total cystic disease fluid protein (GCDFP-15), HMB-45 antigen, high molecular weight melanoma associated antigen (MAGE), ... high molecular weight melanoma associated antigen (MAGE), CD45, CD99, CD117, high molecular weight melanoma associated antigen (MAGE), CD45, CD99, CD117, high molecular weight melanoma associated antigen (MAGE), CD45, CD99, CD117, high molecular weight melanoma associated antigen (MAGE), CD45, CD99, CD117, Melanoma antigen recognized by T lymphocytes (HMW-MAA), protein melan-A (melanoma antigen recognized by T lymphocytes; MART-1), Myo-Dol, muscle-specific actin (MSA), neurofilament, neuron-specific enolase (NSE), placental alkaline phosphatase, synaptophysin, thyroglobulin, thyroid transcription factor-1, dimer of pyruvate kinase isoenzyme type M2 (tumor M2-PK), abnormal ras protein, abnormal p53 protein, fuc-GMl, GM2 (tumor fetal antigen-immunogenic-1; OFA-I-1); GD2 (OFA-I-2), GM3, GD3, α-actinin-4, Bage-1, BCR-ABL, BCR-Abl fusion protein, β-catenin, CA15-3 (CA27.29 / BCAA), CA195, CA242, CA-50, CAM43, Casp-8, cdc27, cdk4, cdkn2a, Coa-1, dek-can fusion protein, EBNA, EF2, Epstein-Van virus antigen, ETV6-AML1 fusion protein, HLA-A2, HLA-A11, hsp70-2, KIAAO205, Mart2, Mum-1, 2, 3, neo-PAP, myosin class I, OS-9, pml-RARa fusion protein, PTPRK, triosephosphate isomerase, Gage3,4,5,6,7, GnTV, Herv-K-mel, Lage-1, NA-88, NY-Eso -l / Lage-2, SP17, SSX-2, TRP2-Int2, gplOO(Pmel17), tyrosinase, TRP-1, TRP-2, MAGE-1, MAGE-3, RAGE, GAGE-1, GAGE-2, pl5(58), RAGE, SCP-1, Hom / Mel-40, PRAME, HER-2 / neu, E2A-PRL, H4-RET, IGH-IGK, MYL-RAR, human papillomavirus (HPV) antigens E6 and E7, TSP-180, pl85erbB2, pl80erbB-3, c-met, nm-23Hl, PSA, TAG-72-4, CA19-9, CA72-4, and CAM17.1, NuMa, 13-catenin, Mum-1, pi6, TAGE, PSMA, CT7, telomerase, 43-9F, 5T4, 791Tgp72, 13HCG, BCA225, BTAA, CD68 / KP1, CO-029, FGF-5, G250, Ga733(EpCAM), HTgp- 175, M344, MA-50, MG7-Ag, MOV18, NB / 70K, NY-CO-1, RCAS1, SDCCAG16, TA-90, TAAL6, TAG72, TLP, TPS, CD19, CD22, CD27, CD30, CD70, EGFRvIII (epidermal growth factor receptor barrier) riant III), sperm protein 17 (Spl7), mesothelin, PAP (prostatic acid phosphatase), prostein, TARP (T cell receptor gamma alternative reading frame protein), Trp-p8, STEAP1 (six transmembrane epithelial antigen 1 of the prostate), integrin ανβ3 (CD61), galactin, Ral-B, FLT3, CD70, DLL#, CD5, GUCY2C, EGFR, KREMEN2, PSMA, ALPPL2, CLDN6, CLDN18, GPR143, GRM8, LPAR3, GD2, ADAM12, LECT1, TMEM186, etc. EXAMPLES
[0095] Working Example Below is a non-limiting description of the test methods and materials used in the examples below.
[0096] Example 1 - K562 clone sequencing As described above, in some embodiments, feeder cell lines are used to expand both NK cells and T cells from a donor blood sample. This example was performed to distinguish from modified K562 populations.
[0097] In view of the above, in some embodiments, preliminary steps are performed to adjust the relative ratio of certain cell types within the population of immune cells isolated from the donor. For example, in some embodiments, a portion of T cells can be selectively removed from the initial sample to prevent T cells from overwhelming NK cells during the expansion process. In some embodiments, any ratio of NK cells to T cells can be achieved by such preliminary steps. For example, in some embodiments, a 1:1 ratio of NK:T cells is used at the beginning of expansion. In further embodiments, NK cells can be enriched in the starting material pool relative to T cells, if desired. For example, in some embodiments, a starting ratio of NK:T cells of about 1000:1 to about 10:1 is used, including about 1000:1, about 750:1, about 500:1, about 250:1, about 100:1, about 75:1, about 50:1, about 25:1, about 10:1, or any ratio therebetween as expressly described.
[0098] As shown in FIG. 2, limiting dilution was applied to the population of K562 cells to generate a smaller number of individual K562 clones for screening. The starting K562 cells were engineered to express 4-1BBL as well as membrane-bound IL15. In some embodiments, the K562 cells can be further modified to express one or more additional stimulatory molecules, such as IL12 and / or IL18. In further embodiments, the K562 cells need not be modified, but are modified if desired, and the culture medium is supplemented with one or more such additional stimulatory molecules. Detailed information regarding such K562 cells is described in PCT Application No. PCT / SG2018 / 050138, filed March 27, 2018, the entire contents of which are incorporated herein by reference. In this particular example, which is also applicable to other embodiments, the K562-41BBL-mbIL15 clone was also engineered to express a single-chain fragment variable (scFv) of the OKT3 antibody, a murine monoclonal antibody of the immunoglobulin IgG2a isotype. This antibody targets CD3, which is part of a multi-molecular complex present only in mature T cells. The interaction of T cells with OKT3 activates the T cells. The mouse OKT3 antibody reacts with an epitope on the epsilon subunit of the human CD3 complex, and therefore can enhance the ability of K562 cells, which stimulate NK cells, to stimulate T cells. Cloning at limited dilutions allows for the identification of different subclones that may express different amounts of the introduced genes (here mbIL15, 4-1BBL and scFv OKT3). In particular, variability in the expression of genes introduced into the feeder cells may result in different characteristics with respect to the proliferation of immune cells. In other words, a given clone can grow NK cells more robustly (e.g., efficiently) than T cells. In some embodiments, a given clone can grow T cells more robustly (e.g., efficiently) than NK cells. In yet another embodiment, a given clone may result in an expanded population of immune cells that are generally healthier, can survive longer, are more effective against target cells, etc.Identifying clones with specific growth characteristics is useful in tailoring the final composition of the mixed cell population. For example, if a particular clone is found to grow NK cells twice as fast as T cell growth, and one wishes to form a mixed cell population with a ratio of about 2:1, one can use this clone to grow the starting population to that desired ratio. In some embodiments, two or more clones can be used to grow immune cells independently, and the final mixed cell population can be a combination of the independently grown immune cell populations. In such an approach, a given clone can be selected based on its ability to preferentially grow a particular immune cell type. For example, in the case of a mixed population of NK cells, cytotoxic T cells, and gamma delta T cells, three clones can be utilized to grow one of these three populations, and the selected clone is selected for having beneficial characteristics to grow one of the cell types.
[0099] In this example, 24 clones were identified and clonally expanded (each clone was clonally expanded for 3 weeks), but larger numbers of clones can be readily prepared. After clonal expansion, K562 cells (pretreated with mitomycin C) were cultured at 5×10 per well. 5 Cells were plated (24-well plates). Gas-permeable membrane culture vessels were used in this study (G-Rex, Wilson Wolf, ST Paul Minnesota). In other embodiments, standard culture vessels can be used. 5×10 cells were plated from each of the four donors. 5 Immune cells (NK cells and T cells) were plated on day 0, and each sample was plated with a clonally expanded K562 population. Cultures were supplemented with 40 U / mL IL-2 on days 0 and 4, and a higher concentration of 400 U / mL IL-2 was added on day 6 of co-culture. Co-cultures were performed for a total of 20 days.
[0100] Figures 3A-3B show data related to the proliferation of NK cells (Figure 3A) and T cells (Figure 3B). Together, these data indicate that both NK cells and T cells can be expanded using clonally derived K562 cell populations as feeder cells. As shown in Figure 3A, certain clones showed particularly effective NK cell proliferation. In particular, Figure 3A shows that clonal K562 feeder cells induce NK cell proliferation ranging from about 15-fold to about 90-fold, depending on the clone and donor used. Figure 3B shows that T cell proliferation was strongly stimulated by all K562 clones tested, with about 50-fold to about 350-fold proliferation, depending on the clone and donor tested. T cell doubling times were about 24 hours or less for all donors. These data indicate that not only is it possible to expand both NK cells and T cells in the same culture, but robust proliferation of individual cell types can occur.
[0101] Figures 4A-4B show data from expanding mixed populations of NK and T cells from each of four donors over a 7-day period using each of the 24 K562 clones as feeder cells. In summary, the composition of the expanded cell population largely reflects the ratio of NK cells to T cells. As shown in Figure 4A, NK cells after expansion ranged from about 2% to about 23% of the cells in the parent sample (e.g., roughly comparing the total number of cells present in the total population after expansion compared to the same percentage from the original donor sample shown in Figures 1A-1D). Figure 4B shows similar data for T cells, whose percentages ranged from about 65% to about 95% of the parent population. In general, the respective NK:T cell ratios after expansion reflect the relative ratios from the original sample (e.g., those in Figures 1A-1D). Thus, in some embodiments, the starting NK cell to T cell ratios can be used as a guideline for the final NK cell to T cell ratios resulting after expansion. As noted above, in certain embodiments, initial adjustments to cell ratios before expansion begins can be used to dictate the final ratios of different cell types to one another after expansion is completed. Additionally, as described in more detail below, method modifications can be implemented during expansion to further fine-tune the ratios of cells that result after expansion.
[0102] Example 2 - Dual Modality Expansion of Mixed Cell Populations As described above, NK cells and T cells can be expanded together in culture, resulting in a ratio of cell types that approximately reflects the starting ratio of cells from the initial blood sample. This example was undertaken to implement a dual-modality expansion protocol that allows for tuning of the relative expansion rates of NK cell and T cell subpopulations.
[0103] FIG. 5 shows an outline of the study design carried out. The expansion timeline and initial seeding of cells are substantially similar to those described above, but cultures are exposed to supplemental growth stimuli at various times after the initiation of co-culture or maintained as described above (as a control). The schematic in FIG. 5 shows that supplemental growth stimuli were added with matrix covering the first 6 days of co-culture. In this example, as described above, the supplemental growth stimuli include the addition of CD3 / CD28 Dynabeads to the culture to stimulate T cell proliferation. In further embodiments, these (or other) supplemental growth stimuli can be added - for example, one or more antibodies can be added directly to stimulate T cell proliferation. As shown in the schematic, cultures are supplemented with IL-2 at various times and FACS analysis is used to assess growth factors and NK:T cell ratios, as well as transduction efficiency during and after expansion.
[0104] Figures 6A-6B show data related to proliferation of NK cells (Figure 6A) and T cells (Figure 6B) measured after 7 days of culture, when CD3 / CD28 polystyrene beads (beads coated with anti-CD3 and anti-CD28 antibodies as a supplemental proliferation stimulus for T cells) were added at various times after the initiation of proliferation. In other words, the day 2 column is the relative proliferation of NK cells or T cells when CD3 / CD28 polystyrene beads were added on day 2 and proliferation was measured on day 7 (5 days of incubation with beads). Figure 6A shows, first, that the addition of CD3 / CD28 polystyrene beads did not adversely affect NK cell proliferation. As shown in the "no beads" data points, the expansion of fold changes was comparable to that shown in the data in Figure 3A. Addition of CD3 / CD28 polystyrene beads between day 0 (the beginning of co-culture) and day 6 of culture did not significantly alter NK cell proliferation in any of the four donors, with each population still showing approximately 15-fold to approximately 85-90-fold proliferation at their peak. Furthermore, NK cell proliferation was relatively consistent over time within a given donor. For example, donor 669 consistently showed an approximately 40-fold increase in NK cells in the absence of beads or when beads were added at any time within the first 6 days of culture. In some embodiments, the addition of CD3 / CD28 polystyrene beads may actually enhance NK cell proliferation rather than simply inhibiting the process.
[0105] Figure 6B shows relevant data on T cell proliferation with the addition of CD3 / CD28 polystyrene beads as a supplemental proliferation stimulus. In contrast to NK cells, T cell proliferation differs markedly with and without CD3 / CD28 polystyrene beads and with the timing of their addition. As shown in the "no beads" section, little to no T cell proliferation occurred in the absence of CD3 / CD28 polystyrene beads when measured on day 7. As can be seen from the general shape of the curves in Figure 6B, T cells proliferated more robustly when CD3 / CD28 polystyrene beads were added early in the culture process. For example, the addition of CD3 / CD28 polystyrene beads at the start of the coculture with NK cells and K562 feeder cells led to a nearly 100-fold increase in T cells in all donors. This induction dropped to a ∼75-fold increase when beads were added after 1 day of culture. The relative proliferation continued to decline the later the beads were added. Thus, in some embodiments, maximum T cell proliferation occurs when the supplemental proliferation stimuli are present at an early time point, e.g., at the beginning of co-culture, within about 6 hours of co-culture, within about 12 hours of co-culture, within about 18 hours of co-culture, or within about 24 hours of co-culture. In some embodiments, the relative proliferation of T cells can be fine-tuned based on when the supplemental proliferation stimuli are provided to achieve the desired NK:T cell ratio in the final expanded population. In other words, if the desired final population has a larger ratio of T cells compared to NK cells, the supplemental T cell proliferation stimuli can be provided relatively early in the co-culture process. Alternatively, if the desired final cell population is more evenly distributed between NK cells and T cells, the addition of the supplemental T cell proliferation stimuli can be delayed until later in the co-culture process. Thus, depending on the embodiment, the culture conditions and relative timing of including (or excluding) the supplemental stimuli for expanding T cells can be fine-tuned to control the final ratio of cells in the final expanded immune cell population.
[0106] As described above, in some embodiments, the expanded population of immune cells (e.g., NK cells and T cells) can be administered to a subject in need of treatment on a "raw" basis and / or after incorporation into a pharma- ceutically acceptable carrier. However, in some embodiments, the cells are genetically engineered with chimeric constructs to enhance cytotoxicity against target cells (see, e.g., PCT Patent Application No. PCT / US2018 / 024650, filed March 27, 2018, the entire contents of which are incorporated herein by reference). To evaluate the potency of the expanded population of NK cells and T cells, tests were performed to determine the ability to transduce the cells.
[0107] Co-grown NK and T cells were transduced with a gamma retrovirus encoding green fluorescent protein (GFP). Cells were transduced on day 7, and transduction efficiency was measured by FACS on days 10 and 14. The data are shown in Figures 7A to 7D. Figure 7A shows the percentage of GFP-positive NK cells relative to total NK cells present in the cultures on day 10 for each donor, depending on the presence or absence of CD3 / CD28 polystyrene beads ("no beads" control) or the time of addition of beads relative to the start of the co-culture with T cells and K562 feeder cells. As shown, neither the presence or absence of beads nor the timing of their addition appeared to have a significant effect on the transduction efficiency of NK cells on day 10. Overall, in all four donors, transduction efficiency ranged from about 80% to about 95% (compared to the starting population of NK cells in the original blood sample collected). Similarly, T cells were also readily transduced on day 10, as shown in Figure 7B. Although the transduction efficiency on day 10 appears to be slightly lower compared to NK cells, in all four donors the efficiency ranged from ≈25% to ≈65% (compared to the starting population of NK cells in the original blood sample collected).
[0108] Analysis of transduction efficiency up to 14 days after the start of co-culture showed that the stability of transgene expression in both transduced NK and T cells was maintained at least until the second week of culture, regardless of initial donor variability and the presence or absence of CD3 / CD28 beads or the timing of the addition of CD3 / CD28 beads. These data are shown in Figure 7C (for NK cells) and Figure 7D (for T cells). Figure 7C shows that transduction efficiency remained between about 78% and 95% in all donors, regardless of the addition or timing of CD3 / CD28 beads to expand T cells. Similar to T cells on day 10 of co-culture, the transduction rate of T cells ranged from about 30% to about 70% on day 14 in all four donors. Together, these data show that both NK and T cells not only readily expand in the presence of each other, but also that each cell type is amenable to transduction, indicating that the cells can be genetically engineered to enhance the cell-promoting effect on target cells.
[0109] As mentioned above, the NK:T cell ratio can be adjusted based on the conditions used during the expansion period (and specific steps can be taken to adjust the ratio of the starting cell populations or to adjust it after expansion). To examine how the timing of CD3 / CD28 bead addition affects the NK / T cell ratio, the proportion of each cell type in the final culture was measured on days 7 and 14, and the results are shown in Figures 8A-8D. Figure 8A shows the NK cell count data on day 7 (either a "no bead control" or each donor's cell population was co-cultured with K562-41BB-mbIL15 cells and CD3 / CD28 beads were added at various time points). Consistent with the relative expansion of each cell type, Figure 8A shows an interesting trend of increasing the proportion of NK cells in the final culture as CD3 / CD28 beads are added later in the expansion period. Interestingly, as shown in Figure 8C, the proportion of NK cells in the final culture continues to increase on day 14, and for some donors, nearly 100% of the cells present in the initial sample were NK cells. This is also noteworthy in that the assessment was at day 14 post-transduction, indicating that NK cells do not lose their proliferative capacity as a result of transduction with exogenous vectors, whereas T cells may require earlier stimulation or become exhausted during the culture period.
[0110] In contrast to NK cells, the addition of CD3 / CD28 beads during the culture period reduces the proportion of T cells. T cell populations exposed to beads later in the co-culture period show a decrease in the overall proportion of T cells. This is likely due to the shortened period during which those T cell populations were exposed to the stimulatory effects of CD3 / CD28 beads. The data in Figure 8D also show that the proportion of T cells declines during the second week of culture, as represented by the data from day 14. These data show that the proportion of T cells at day 14 peaked at approximately 70% of the parental cell number, but fell to as low as 1-2% (e.g., for samples in which CD3 / CD28 beads were added on days 4, 5, or 6 of co-culture). This may reflect the effect of a shorter period of stimulation of T cells and / or the removal of a large number of stimulatory beads during the transduction protocol. It may also reflect T cell exhaustion. However, taken together, these data show that there is a trend toward an increase in NK cells and a decrease in T cells over the 2-week co-culture period. With knowledge of this general behavior, culture conditions can be adjusted to optimize the rate of NK cell expansion and T cell depletion to obtain a post-expansion mixed cell population with desired characteristics.
[0111] Taken together, this test data (similar to Example 1) shows that NK cells and T cells can be successfully co-expanded according to some embodiments described herein. According to some embodiments, NK cells and T cells can be co-expanded simultaneously by co-culturing the two immune cell populations with K562 cells, which in some embodiments are modified to express 4-1BBL and / or mbIL15. In yet additional embodiments, the K562 cells are further modified to present specific T cell stimulatory signals, such as, for example, antibodies or other molecules that interact with and stimulate the proliferation of T cells. In some embodiments, the K562 cells are modified to express OKT3 antibodies. Alternatively or additionally, according to some embodiments, a separate T cell stimulus is provided. For example, according to some embodiments, anti-CD3 and / or anti-CD28 antibodies are provided to stimulate T cell proliferation. Thus, these data show that there are multiple different ways in which NK cells and T cells can be co-expanded. Advantageously, the choice of method used can be tailored depending on the desired ratio of NK cells to T cells in the final expanded immune cell population. For example, data provided herein show that the K562.41BBL.mbIL15.scFv-OKT3 clone can expand NK cells while robustly expanding T cells. Thus, such an approach is preferred when a high T:NK cell ratio is desired. Furthermore, certain K562 clones have been identified that result in high NK ratios after expansion. Thus, in some embodiments, such clones can be used when a more balanced ratio of NK cells to T cells is desired. Furthermore, rather than incorporating T cell stimulation into the feeder cell line, feeder cell lines engineered to preferentially expand NK cells can be combined with another supplemental T cell expansion stimulus if more control over the final NK / T cell ratio is desired. According to some embodiments, this can be achieved by combining feeder cells, such as K562.41BBL.mbIL15 feeder cells, with, for example, CD3 / CD28 T cell stimulating beads.The timing of the introduction of separate T cell stimuli can also be used to fine-tune the final ratio of NK cells to T cells. For example, a higher NK:T ratio can be achieved by introducing T cell stimuli later in the co-culture process, while a higher T:NK ratio can be achieved by introducing separate T cell stimuli earlier in the co-culture process. Thus, the expansion methods described herein are advantageously flexible with respect to adjusting the various starting materials and procedures, ultimately resulting in a composite immune cell population with the desired ratio between the various cell types in the resulting expanded population.
[0112] Example 3 - Model system for assessing mixed immune cell populations As can be appreciated, the development of novel mixed cell populations described herein, performed by various embodiments of the methods described herein, may require innovative evaluation panels. Thus, in some embodiments, specific model systems are provided for evaluating one or more of the survival, proliferation, persistence, intravasation and / or efficacy (e.g., cytotoxicity) of mixed immune cell populations.
[0113] Figures 9A-9C show schematics for the generation of various custom cell types to evaluate the efficacy of composite immune cell populations. Daudi cells are B-lymphoblastic suspension cells derived from a patient with Burkitt's lymphoma. As shown in Figure 9A, lentiviral constructs can be used to transfect Daudi cells with various reporters, such as green fluorescent protein (GFP), nuclear red (NucRed), and CD19 (lacking the intracellular domain) coupled to firefly luciferase (fflucCD19). As shown in Figure 9B, Raji cells, another human B-lymphoblastic suspension cell line, are genetically engineered in a similar manner. Figure 9B shows a schematic for the introduction of CD19 (lacking the intracellular domain) and luciferase into HL60 cells, a human myeloblastic suspension cell line. These NucRed and GFP constructs were used for in vitro testing, and the firefly luciferase construct was used for in vivo testing. Each CD19 construct (lacking the intracellular domain) was engineered to express CD19 on tumor cells that do not normally express CD19, and could be targeted by NK cells and T cells engineered to elicit cytotoxic effects against CD19-expressing target cells. Functional evaluation was also performed using kinetic cell death assays to determine the timeframe in which NK cells and T cells, respectively, elicit their cytotoxic effects against target cells.
[0114] CD19-expressing HL60 target cells were used in a re-exposure assay to assess the cytotoxic effect of NK cells alone, T cells alone, or the combination of NK+T cells. On day 0, NK, T, and NK+T cell populations were exposed to 20,000 CD19-expressing HL60 cells. On day 4, these cell populations were re-exposed with an additional 10,000 CD19-expressing HL60 cells. Target-only cells were cultured under the same conditions but washed with PBS before the second addition of target cells (as a control). The resulting data are shown in Figure 10, where NucRed counts represent the number of live CD19-expressing HL60 cells counted per well.
[0115] As can be seen from the NK(CAR19) curve, NK cells targeting CD19 show rapid initial cell death of target cells. However, after re-exposure on day 4, the number of surviving HL60 cells steadily increased. In contrast, the T cell curve (T(CAR19)) shows a slower rate of initial cell death. Although T cells eliminated most targets, in contrast to the rapid effect with NK cells, T cells took until day 4 to eliminate the first bolus of CD19-expressing HL60 cells. Even after exposure to additional HL60 cells on day 4, T cells maintained a stable cytotoxic effect against CD19-expressing HL60 cells.
[0116] NK+T cell populations were generated by replacing 50% of a population of NK(CAR19) cells with T(CAR19) cells. When initially exposed with CD19-expressing HL60 cells, the NK cell portion of the population retained the ability to induce rapid cell death of target cells. However, in contrast to the NK-only population, re-exposure with CD19-expressing HL60 cells on day 4 resulted in a long-lasting cytotoxic effect of T cells, with the overall cytotoxic effect after re-exposure being similar to that of the T cell-only population. As shown in this study, when the total number of effector cells (NK, T or NK+T) was held constant, NK+T (1:1 ratio) showed a more rapid cell death effect than T(CAR19) alone and a more sustained cell death effect than NK(CAR19) alone.
[0117] Thus, the NK+T cell population advantageously retained both rapid and sustained cell death effects. This "mixed" cytotoxicity provides several advantages in cancer immunotherapy. It is known that many cancers are adaptive and have "camouflage" mechanisms to avoid detection by the immune system. The rapid cell death effect of NK cells in the NK+T mixed population helps eliminate cancer cells before such camouflage effects can work. Furthermore, even if cancer cells are killed quickly, a small number of cells may remain, which may lead to tumor recurrence. Therefore, the T cell portion of the NK+T cell population can induce long-term cytotoxic effects and reduce the risk of recurrence. Although this study demonstrated a 1:1 ratio of effector cells (NK:T) as described above, in some embodiments, other ratios can be achieved with the methods described herein. In some embodiments, the final ratio can be adjusted to suit the particular treatment situation. For example, slow-growing tumors can be optimally treated with a lower NK:T ratio, which may also drive cytotoxicity kinetics toward slower but longer-lasting anticancer effects. In contrast, for aggressive tumors, a higher NK:T ratio may be desired, since the initial fast cytotoxicity kinetics achieves rapid destruction of tumor cells and / or tumor elimination, while the longer T cell kinetics "cleans up" the rest of the tumor. Similarly, in some embodiments, different ratios of NK+T cell populations can be administered at different times during the patient's treatment. For example, a high cytotoxic ratio of NK:T cell populations can be administered early in the treatment to suppress early tumor growth, and then transition to a lower ratio of NK:T cell populations to maintain efficacy and suppress tumor growth in the long term (such as a drug loading dose followed by a maintenance dose).
[0118] Example 4 - Functional evaluation in three-dimensional culture To more easily recapitulate the natural environment of some tumors, especially solid tumors, 3-D culture systems have been developed to model intratumoral infiltration and to test how mixed immune cell populations react and perform in the modeled tumor microenvironment.
[0119] FIG. 11 is a schematic diagram of one such model environment. VersaGel® (Cypre, Inc. San Francisco, CA) is a hydrogel that can be used to encapsulate cells and has optical properties suitable for downstream optical imaging to analyze the cells. VersaGel® was placed in the center of a 96-well culture dish and 10,000 CD19-expressing HL60 cells were seeded into the gel. The top left of FIG. 11 shows the seeded cells on day 0; note that there are cells in the central region of the well that mark the edge of the gel, and a circular area on the outside where a regular culture well would be. The bottom left panel shows a representative culture well on day 8, with the center inset showing spheroid formation. The left portion of the inset shows that spheroid formation is restricted to the region of VersaGel®, the dotted line shows the division between the gel and regular culture medium, and the right portion shows regular cell culture growth of HL60 cells. The top right portion of Figure 11 shows a short exposure visualization of a NucRed-expressing HL60 spheroid (labeled / arrow). A longer exposure (bottom left) shows a single NucRed-expressing HL60 cell that is outside the VersaGel® boundary and therefore has not formed a spheroid.
[0120] In some embodiments, spheroids can reproduce 3D tumor microenvironment and test how immune cells such as mixed population of NK+T cells function in the reproduced tumor microenvironment.For example, this approach can be used to test the ability of NK+T cell population to infiltrate tumor and exert cytotoxic effect deep inside tumor, instead of just acting on surface cells.
[0121] In some embodiments, 3D tumor spheroids are exposed to various ratios of NK+T cell populations, and tumor cell viability is assessed, for example, by detection of red channel fluorescent signal in the case of CD19-expressing NucRed-expressing HL60 (or other) tumor cells. In some embodiments, the mixed population of NK+T cells may exhibit enhanced cytotoxic activity compared to either NK cells alone or T cells alone. Similarly, in some embodiments, the mixed population of NK+T cells may exhibit enhanced tumor infiltration compared to either NK cells alone or T cells alone. In some embodiments, the ratio of NK cells to T cells can be varied to alter the kinetics of cytotoxicity, as described above, to achieve an initial rapid onset of cytotoxic effect followed by a prolonged cytotoxic effect, or a ratio that results in a slower initial phase (based on T cells) and a more prolonged cytotoxic phase.
[0122] Example 5 - Evaluation of combined NK and T cell therapy Further tests were performed both in vitro and in vivo to further evaluate the beneficial interactions of NK cells and T cells in combination therapy. As described above and in more detail based on the experimental data below, in some embodiments, NK cells and T cells were found to interact synergistically in terms of cell proliferation and their cytotoxic effects on target tumor cells. As outlined in the tests below, the interaction between NK cells and T cells was evaluated in terms of cytotoxicity (using a matrix assay) and persistence of cytotoxicity (using a tumor re-exposure assay). In addition, tests were performed to elucidate the cellular mechanisms that lead to the synergistic effects of NK cells and T cells. The cytokine profiles of NK cells and T cells were also evaluated, as well as the in vivo antitumor effects in xenograft mouse models.
[0123] The objective of this study was to determine whether a combination of NK cells and T cells could achieve efficient tumor killing activity, increased durability of activity and improved cytokine release in terms of improved patient safety (e.g., a cytokine release profile that reduces the risk of cytokine release syndrome).
[0124] FIG. 12A shows a schematic matrix for evaluating various concentrations of NK cells and T cells expressing anti-CD19 CAR (as a non-limiting example of chimeric antigen receptor) and the resulting cytotoxic effect on Nalm6 tumor cells (as an example of a target cancer type). For the CAR construct used in this study, which is a non-limiting example of a CAR that can be used for NK cells and T cells used in the embodiments described herein, the anti-CD19 conjugate is FMC63 scFv. In some embodiments, the conjugate is humanized. In the studies described herein, the CAR has a Flag tag, but it can be understood that in some embodiments, for example, in clinical constructs, no tag is used. In some embodiments, the CAR comprises an OX40 costimulatory domain and a CD3 zeta stimulatory domain. In some embodiments, the nucleic acid encoding the CAR further encodes an IL15 domain. In some embodiments, IL15 is expressed separately by NK cells and / or T cells as a membrane-bound polypeptide. As shown in the figure, T cells expressing this construct are designated as T19-1 and NK cells expressing this construct are designated as NK19-1. Figure 12A shows various ratios of T19-1 to Nalm6 on the X-axis of the matrix (T19-1=0, or shown as 1:1, 1:2, 1:4, or 1:8). The Y-axis shows various ratios of NK19-1 to Nalm6 (NK19-1=0, or shown as 1:1, 1:2, 1:4, 1:8, or 1:16). By following the intersection of the X-axis and Y-axis, it is possible to ascertain what ratios of NK cells and T cells were present relative to the Nalm6 target cells. The Nalm6 target cells are a CD19-positive B cell precursor leukemia cell line that also stably expresses NucRed, which can be used as an indicator of Nalm6 cell survival (and thus correlates with NK / T cell cytotoxicity).
[0125] Figure 12B shows the results of a study in which a decrease in red fluorescent signal correlates with stronger cytotoxicity against Nalm6 tumor cells. As can be seen from the data, decreasing the E:T ratio (for either NK or T cells) increases the survival rate of Nalm6 cells. For example, see T19-1:Nalm6 at 1:8 and NK19-1=0 (pair of circular images at the top right). At this E:T, T cells were unable to produce significant cytotoxic effects against Nalm6 target cells. Similarly, Nalm6 cells continued to proliferate in the presence of both NK and T cells at low concentrations (see the pair of circular images at the bottom right for T19-1 at 1:8 and NK19-1 at 1:16). However, at many other E:T ratios, the combination of NK and T cells worked together to exert a strong antitumor effect. As can be seen, when either NK19-1 or T19-1 cells were present at a 1:1 E:T ratio, Nalm6 proliferation was almost completely blocked, regardless of the ratio of other effector cells to tumor cells. Similar results were seen when either NK cells or T cells were present at a 1:2 E:T ratio. These 1:1 E:T ratios were gradually decreased (using each effector cell type alone). Notably, Nalm6 proliferation was observed when NK19-1 cells were used alone at an E:T ratio of 1:2, and when T19-1 cells were used alone. However, when T cells and NK cells were combined at an E:T ratio of 1:2, resulting in a 1:1 effector-to-target ratio, Nalm6 proliferation was abolished. These results indicate that NK cells and T cells act synergistically with each other. Neither cell type alone could suppress Nalm6 proliferation at a 1:2 ratio, but when combined at concentrations that were "ineffective" when used alone, the NK+T cell combination enhanced the cytotoxic effect (see image in dashed box labeled "(NK+T):Nalm6=1:1"). The synergistic effect of NK and T cells was more pronounced when the two cell types were combined at an effector-to-target ratio of 1:4, respectively. Both NK and T cells enabled significant proliferation of Nalm6 when used alone at a 1:4 ratio.However, we found that combination of NK and T cells at an E:T ratio of 1:4 significantly suppressed Nalm6 proliferation and enhanced cytotoxicity compared with either cell alone at an overall ratio of 1:2. Again, these data suggest that combination therapy with both NK and T cells allows the two immune cell types to act synergistically with each other to enhance the cytotoxic effect against target cells.
[0126] Figure 13 shows additional data related to the enhanced ability of mixed populations of NK and T cells to cytotoxically affect target tumor cells. The data shown in Figure 13 shows the proliferation of Nalm6 tumor cells in a re-exposure model using T cells or NK cells alone, and a combination of NK and T cells. The first exposure to tumor cells was at time zero of the study, and the second exposure was 7 days later. As can be seen, only the targeted tumor cells proliferate significantly during the first 7 days and the second re-exposure. When T cells were used alone (in this non-limiting study, the T cells express anti-CD19 CAR), there was a continuous proliferation of Nalm6 cells during the first 7 days. The second exposure caused a surge in target cell proliferation, but the level remained almost constant during the study. NK cells expressing anti-CD19 CAR according to some embodiments described herein effectively controlled proliferation during the first exposure period. There was a slight delay in target cell proliferation immediately after the second exposure, but thereafter the target tumor cells proliferated significantly. However, in particular, the combination of NK cells and T cells controlled the proliferation of target cells during the first and second exposure periods, effectively blocking the proliferation of target cells throughout the entire test period. These data indicate that the combination of NK cells and T cells not only enhances cytotoxicity (as can be seen from the results above), but also enhances the persistence of cytotoxicity. According to some embodiments, this enhanced persistence not only prolongs the duration of cytotoxicity against target cells, but also shortens the administration interval, which is advantageous in suppressing potential side effects.
[0127] Further studies were performed to clarify some of the mechanisms of the combination of NK and T cells. It is noted that the combination of NK and T cells at least resulted in a qualitative increase in immune cell numbers, leading to the investigation of whether the increased cell numbers mediate the increased persistence observed. In addition, we aimed to clarify whether the increased cell numbers were due to an increase in NK cells, T cells, or a combination thereof. Figures 14A-14B show cell count data collected using a combination of fluorescent cytotoxicity assays (used in the studies above) and cell phenotyping by FACS. These data were collected on day 7 after mixing immune and target cells. Figure 14A shows NK cell counts using the indicated NK:target (Nalm6) ratios (trace) at the indicated T:target ratios (X-axis). Again, as a non-limiting embodiment, both the NK and T cells in this study were genetically engineered to express anti-CD19 CAR (19-1). As shown in the bottom trace (black circles), when the NK cell input number was zero, no NK cells were detected at any T cell:target ratio. In contrast, when the NK cell:Nalm6 ratio was 1:4, lowering the T cell:Nalm6 ratio (e.g., more T cells were present) increased the number of detected NK cells (black squares). NK cell numbers increased nonlinearly from 1:8 to 1:4 T cell:Nalm6 ratios compared to 1:2. This general pattern was also detected at lower NK cell:Nalm6 ratios (1:2, black triangles). Notably, in the absence of T cells, NK cell proliferation was limited regardless of the starting number of NK cells (see T19-1=0). When T cells were present at a ratio of 1:16, starting with NK:Nalm6 ratios of 1:2 or 1:4 did not change NK cell numbers (indicating NK cell proliferation). However, at higher relative concentrations of T cells, samples with a 1:2 NK:Nalm6 ratio induced a higher degree of NK cell proliferation. Figure 14B shows the corresponding data relating to the measurement of T cell numbers in the presence of various concentrations of NK cells.Each trace is associated with one of the ratios of T cells to Nalm6 target tumor cells, and the x-axis shows the various concentrations of NK cells:Nalm6 target tumor cells. Except for two traces where the T cell:Nalm6 ratio was 1:4 or 1:2, NK cells had little effect on T cell numbers. However, in the presence of NK cells:Nalm6 ratios of 1:4 or 1:2, the final T cell numbers were significantly reduced (see the closed inverted triangle and closed diamond traces).
[0128] Additional investigations were performed to monitor whether the changes in cell number were due to changes in cell proliferation. An approach was used to monitor the change in fluorescence with increasing cell numbers. In this method, a fluorescent dye is added to cells at time zero (using ThermoFisher's CellTrace™ Violet Cell Proliferation Kit Violet). At every mitosis of the parent cell, the fluorescence signal decreases synchronously as it is divided into two cells. Similarly, at the second mitosis, each of the two first generation daughter cells gives rise to two granddaughter cells, and the relative fluorescence signal decreases accordingly. Thus, in this assay, a decrease in the fluorescence signal corresponds to the proliferation of the labeled cells. In these studies, both NK cells and T cells were genetically engineered to express non-limiting aspects of the anti-CD19 CAR, as described above, allowing them to exert a cytotoxic effect on Nalm6 target cells. After gene transfer, NK cells and T cells were co-cultured and cell proliferation fluorescence analysis was performed. Nalm6 cells were exposed to the NK / T cells and incubated for 6 days. The cells were then stained with CD56-PE dye and CD3-APC dye to identify CD56 + CD3 - or CD56 - CD3 +FACS analysis was performed using the gates for cells (NK cells or T cells, respectively) to detect NK cells or T cells. The resulting data of the FACS analysis are shown in Figures 15A-15E. Each of Figures 15A-15E shows NK cell counts with an increased number of T cells (decreased T cell:Nalm6 ratio) and a 1:1 NK19-1:Nalm6 ratio. As can be seen, with each increasing number of T cells, the CD56 + CD3 - The slope of the curve gated at becomes wider, indicating an increasing number of proliferating NK cells. The data are summarized in Figure 15F, which shows two curves: a 1:1 NK19-1:Nalm6 ratio (raw data from Figures 15A-15E) and a 2:1 NK cell:Nalm6 ratio showing NK cell proliferation. This summarized data shows that NK cell proliferation increases in sync with the presence of T cells, which increases the NK cell proliferation.
[0129] Corresponding data are shown in Figures 16A-16D for T cells. Figures 16A-16C measure the number of T cells in the presence of successively increased numbers of NK cells (NK=0 in A, NK:Nalm6=1:1 in B, NK:Nalm6=2:1 in C). The ratio of T cells:Nalm6 was 1:2. In contrast to the curves shown in Figure 15, the signal associated with proliferating T cells continuously decreases with increasing numbers of NK cells. These data are summarized in Figure 16D and show that the proportion of proliferating T cells consistently decreases with increasing ratio of NK cells to target cells. Most noteworthy is the substantial decrease detected using the most dilute T cell concentration (1:16 T19-1:Nalm6).
[0130] Without being bound by theory, based on data relating to the promotion of an increase in the number of proliferating NK cells and data showing that an increase in the number of NK cells leads to a decrease in the number of proliferating T cells, a schematic model shown in Figures 17A-17C was developed. Figure 17A shows the proliferation of NK cells alone in the presence of target tumor cells, and the resulting limited proliferation of NK cells expressing CAR. Figure 17B shows the corresponding schematic model when T cells show strong proliferation when alone in the presence of target tumor cells. Figure 17C also depicts the proliferation of NK cells when in the presence of T cells as well as target tumor cells. As shown in the schematic, at least some of the proliferation signals that would otherwise cause T cell proliferation positively affect NK cells. As a result, NK cells (which only had limited proliferation by themselves) proliferate. This is in contrast to the strong proliferation of T cells when cultured alone with target tumor cells, which shows a more limited degree of proliferation in the presence of NK cells. Taken together, these data suggest that the positive effect of T cells on NK cell proliferation appears to be initiated when a threshold population or concentration of NK cells is present. Thus, in some embodiments using a mixed population of NK cells and T cells, the ratio of NK cells to T cells is adjusted to achieve a beneficial effect on NK cell proliferation. Thus, as described above, in accordance with some embodiments described herein, a mixed population of NK cells and T cells can be generated such that the entire population exhibits enhanced cytotoxicity against target tumor cells, as well as enhanced persistence, either or both of which are at least partially due to enhanced T cell-based NK cell proliferation.
[0131] To further elucidate the mechanisms that play a role in the enhanced and sustained cytotoxicity of mixed populations of NK and T cells, a cytokine profile analysis was generated and the results are shown in Figures 18A-18L. Data were collected using cells from two different donors. For each donor, analysis of cytokine production by NK and T cells was measured using a mixed population of NK cells (either NK=0, NK:Nalm6=1:4, or NK:Nalm6=1:2) in either Nalm6 cells alone (T=0) or in the presence of T cells, with T:Nalm6 ratios of 1:2, 1:4, 1:8, or 1:16. Evaluation was performed on day 5 after starting the co-culture of immune cells with targets. In general, the data in Figures 18A-18L show a decrease in the production of selected cytokines corresponding to a decrease in the amount of T cells, and importantly, cytokines like GM-CSF and IL6 that are associated with potential side effects from T cell therapy, such as cytokine release syndrome. For example, Figure 18A shows the GM-CSF concentration released from T cells of two different donors. These data indicate that at lower T cell:target ratios, less GM-CSF is produced by the cells, reducing the likelihood of CRS. This trend is consistent in the presence of NK cells, but FIG. 18A shows that increasing the number of NK cells in the co-culture reduces the levels of GM-CSF that accumulate in the system, regardless of the starting T cell concentration. Another notable trend is shown in FIG. 18E, which shows that increasing the number of NK cells does not reduce IFNg production, a cytokine important in inducing cytotoxicity against target cells. In other words, the combination of cells used in some embodiments described herein is not self-limiting in that the presence of NK cells together with T cells disrupts the activity of one cell. Rather, as described herein, these two types of cells work in tandem with each other to provide a synergistic cytotoxic effect against target cells. FIG. 18F shows the production of IL2. In the first donor, there was very little IL-2 production by T cells, regardless of the number of NK cells present. In the second donor, IL-2 production was detected by T cells only in the absence of NK cells, but production did not correlate with dose dependency.The presence of NK cells may either change the degree of secretion by specific T cells, or the overall level of T cells contributing to cytokine accumulation, or NK cells may act as a sink for binding secreted cytokines (thus affecting NK cell proliferation or activity). In addition to the cytokines tested here, other cytokines produced by T cells may also contribute directly or indirectly to NK cell proliferation and / or persistence. Advantageously, in some embodiments, the reduction of cytokine production when NK cells and T cells are combined induces enhanced cytotoxicity and persistence of NK cells while cooperatively reversing the risk of cytokine release syndrome.
[0132] To further evaluate the enhanced cytotoxicity and persistence by the mixed population of NK and T cells, a xenograft model was used in which NSG mice were implanted with Nalm6 target tumor cells. Nalm6 cells were engineered to express GFP as well as firefly luciferase, the latter allowing the detection of tumor burden in implanted mice by measuring bioluminescence. Figure 19 shows the schematic study design of the xenograft model. Mice were injected with a combination of NK and T cells engineered to express a non-limiting example of an anti-CD19 CAR (19-1). Tumor cells were injected on day 0, and NK and T cells were injected alone or in combination on day 3 (Figure 20A). In some groups, NK cells were administered on day 3 followed by T cells on day 4, or T cells were administered on day 3 followed by NK cells on day 4 (Figure 20B). Bioluminescence imaging was performed at the intervals shown in Figure 19. Bioluminescence results are shown in Figures 20A-20C, which show data separated by days post-transplant, with the indicated cell doses and order of administration. Figure 20A shows PBS, 2.5 x 10 NK cells expressing the anti-CD19 CAR 19-1 construct, and 6 2.5 × 10 T cells expressing anti-CD19 CAR 19-1 construct 6 pcs or 5×10 5 , a combination of NK cells and T cells (both 2.5 × 106 cells), or a combination of NK cells and T cells (NK cells were 2.5 × 10 6 and T cells are 5x10 5 Figure 20B shows luminescence data from days 2 to 31 after the start of the study for a test group administered 2.5x10 NK cells and 2.5x10 T cells. Figure 20C shows data for the same time frame for a test group administered staggered NK and T cells on days 3 and 4. The left two columns show the results for a test group administered NK cells on day 3 and T cells on day 4, and the right two columns show the results for a test group administered T cells on day 3 and NK cells on day 4. Each group received 2.5x10 NK cells and 2.5x10 T cells. 6 A group receiving 2.5x10 NK cells (high dose) and a group receiving 2.5x10 6 5x10 cells and T cells 5 The subjects were divided into two subgroups: a group administered the cell dose (low dose) and a group administered the cell dose (low dose).
[0133] It is noted that only NK cells inhibited tumor growth more effectively when the cell combination was administered together over the first 30 days of the study compared to the PBS control. In accordance with some embodiments described herein, the combination of high dose NK cells and low dose T cells (rightmost column in FIG. 20A) shows significantly improved tumor control compared to NK cells alone (same dose of NK cells). This treatment group also shows improved tumor control compared to T cells alone (same dose of T cells). In some embodiments, the ratio of NK:T cells not only allows tumor control, but also achieves the same with reduced cytokine release and reduced risk of CRS. Both high dose T cells alone and high dose NK / T cells showed tumor control over 30 days.
[0134] The next most effective treatment in terms of preventing tumor burden growth was a treatment regimen in which the starting dose of NK cells was administered followed by a low dose of T cells the next day (see second column in FIG. 20B). The next most effective treatment was low dose T cells alone, which significantly prevented tumor growth for almost three weeks. The next most effective was a combination of T cells and NK cells, with low dose T cells administered first and NK cells administered one day later. The next most effective was NK cells and low dose T cells administered on the same day. Again, this study is focused on treatment groups that have seen some tumor progression over the first 30 days. However, data from the first 30 days confirm that in some embodiments, a higher ratio of NK cells compared to T cells, for example, about 5:1, about 10:1, or about 20:1 depending on the embodiment, results in robust acute and intermediate cytotoxicity. As noted above, low numbers of T cells can provide sufficient NK-cytotoxicity and NK-proliferative stimulation, while not being so abundant that NK cells cannot suppress T cell proliferation to some extent, thereby reducing T cell-induced cytokine release (and thus reducing harmful inflammatory effects).
[0135] The other groups tested prevented tumor growth until that time point and beyond, as shown in Figure 20C. Without being bound by theory, these data suggest that perhaps there was a more robust initial response in these groups, facilitating long-term control, and / or there may have been some early inhibition or other suppression of T cell proliferation, thereby conferring a longer active lifespan before exhaustion. High doses of T cells and NK cells administered for the first 74 days, with T cells administered on day 3 and NK cells administered on day 4, inhibited tumor growth for approximately 65 days, with significant tumor burden only evident at day 74 after tumor implantation. High doses of T cells alone were also able to significantly slow tumor progression, with only minor tumor growth detectable at day 74. Overall, the two most effective treatments were those combining NK and T cells. NK cells administered on day 3, followed by high doses of T cells on day 4, resulted in virtually no tumor detectable at day 74, with 80% of mice surviving. Similarly, when high doses of both NK cells and T cells were administered on day 3, the effect was even stronger, with 100% of the treated mice surviving with only a faint tumor detectable at day 74 after tumor implantation. This trend continued on days 81-121 after tumor implantation, with the administration of T cells (high dose) followed by NK cells and then a high dose of T cells similarly suppressing tumor growth. Notably, the combination of NK cells and T cells controlled tumor growth more strongly, with the most effective control observed when the combination of NK cells and T cells (high dose) was administered on the same day. Figure 20D shows the survival curves for all groups together, reflecting the bioluminescence data above. Figure 20E shows only selected groups to more clearly demonstrate the enhanced tumor control seen with the combination of NK cells and T cells over a 4-month period. Notably, the administration of NK cells followed by T cells and the administration of NK cells and T cells together show significantly improved tumor control. Taken together, these data indicate that the combination of NK cells and T cells is a highly effective cancer treatment.According to some embodiments, varying the concentration of NK cells and T cells can fine-tune the cytotoxicity as well as the persistence of the combined product to achieve long-term tumor growth control. Similarly, according to some embodiments, the combination of NK cells and T cells does not necessarily have to be administered simultaneously to achieve high efficacy. According to some embodiments, one of the two cell types can be administered at an earlier time point and the other cell type at a later time point. This allows one cell type, such as NK cells, to exert an effect at an earlier time point, which is later synergistically complemented by the cytotoxic and / or growth-promoting effect of the second cell type, such as T cells. For example, depending on the type of tumor to be treated, the order of administration may be altered such that the administration of the first cell type creates a beneficial environment (e.g., an artificial tumor microenvironment) that enhances and / or maximizes one or more properties of the second cell type. In other words, in some embodiments, by sequentially administering the first cell type and the second cell type, the first cell type prepares the tumor microenvironment for optimal cytotoxicity by the second cell type. Moreover, as provided in several embodiments described herein, mixed populations of NK cells and T cells can be co-administered to achieve significantly more effective anti-tumor effects.
[0136] It is contemplated that various combinations or subcombinations of the specific features and aspects of the above embodiments may be made and still fall within one or more of the present inventions. Moreover, the description herein of any particular feature, aspect, method, property, quality, attribute, element, etc., associated with one embodiment may be used with all other embodiments described herein. Thus, it should be understood that various features and aspects of the disclosed embodiments may be combined with or substituted for one another to form various embodiments of the disclosed invention. Thus, it is intended that the scope of the invention described herein should not be limited by the specific disclosed embodiments above. Moreover, the present invention is susceptible to various modifications and alternative forms, examples of which have been shown in the drawings and are described in detail herein. However, the present invention is not limited to the specific forms or methods disclosed, but on the contrary, it should be understood that the present invention encompasses all modifications, equivalents, and alternatives falling within the spirit and scope of the various embodiments described and the appended claims. The methods disclosed herein need not be performed in the order described. The methods disclosed herein include certain actions performed by the practitioner, but may also include explicit or implicit direction of those actions by a third party. For example, an act such as "administering an expanded NK cell population" includes "instructing the administration of the expanded NK cell population." Furthermore, where features or aspects of the disclosure are described in terms of the Markush group, one of skill in the art will recognize that the disclosure is thereby also described in terms of any individual members or subgroups of members of the Markush group.
[0137] Ranges described herein also encompass any and all overlaps, subranges, and combinations thereof. Terms such as "up to," "at least," "greater than," "less than," "between," and the like, include the recited number. Numbers preceded by terms such as "about" or "approximately" include the recited number. For example, "90%" includes "90%." In some embodiments, at least 95% homology includes 96%, 97%, 98%, 99%, and 100% homology to the reference sequence. Furthermore, when a sequence is disclosed as "comprising" a nucleotide or amino acid sequence, such a reference is also intended to include that the sequence "comprises," "consists of," or "consists essentially of" the recited sequence, unless otherwise specified.
[0138] Articles such as "a", "an" and "the" mean one or more unless otherwise indicated or clear from the context. The term "and / or" as used herein and in the claims should be understood to mean "either or both" of the elements so conjoined. Multiple elements listed with "and / or" should be construed in the same manner, i.e., to mean "one or more" of the elements so conjoined. Other elements may optionally be present other than the elements specifically identified with "and / or". "Or" as used herein and in the claims should be understood to have the same meaning as "and / or" as defined above. For example, when used in a list of elements, "or" or "and / or" shall be construed to be inclusive, i.e., to include at least one, optionally one or more, of the list of elements, and optionally including additional unlisted elements. Only terms clearly indicating the contrary, such as "Only one of" or "exactly one of," shall mean the inclusion of exactly one element of a number or list of elements. Thus, a claim including "or" between one or more members of a group is deemed to be satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process, unless indicated to the contrary. Embodiments are provided in which exactly one member of a group is present in, employed in, or otherwise relevant to a given product or process. Embodiments are provided in which multiple members, or all members of a group are present in, employed in, or otherwise relevant to a given product or process. Any one or more claims may be amended to explicitly exclude any embodiment, aspect, feature, element or characteristic, or combination thereof. Any one or more claims may be amended to exclude any agent, composition, amount, dosage, route of administration, cell type, target, cell marker, antigen, targeting site, or combination thereof.
[0139] Any titles or sub-headings used herein are for organizational purposes only and should not be used to limit the scope of the aspects described herein.
Claims
1. 1. A method for generating a mixed population of genetically modified immune cells comprising at least two subpopulations of genetically modified immune cells, comprising: isolating a mononuclear cell population from a blood sample, wherein said isolated mononuclear cell population comprises at least a first immune cell subpopulation and a second immune cell subpopulation; isolating a first immune cell subpopulation from the isolated mononuclear cells; culturing the isolated first immune cell subpopulation in a culture vessel with a population of feeder cells, wherein the feeder cells are configured to express at least one molecule for stimulating the proliferation of natural killer (NK) cells within the first immune cell subpopulation, and wherein the at least one molecule is selected from 4-1BB ligand (4-1BBL), interleukin 15 (IL-15), and combinations thereof, thereby generating an expanded population of NK cells; isolating a second immune cell subpopulation from the isolated mononuclear cells; culturing the second immune cell subpopulation in a culture vessel with at least one molecule for stimulating proliferation of T cells within said second immune cell subpopulation, wherein the at least one molecule for stimulating proliferation of T cells comprises one or more of an antibody against CD3 or an antibody against CD28, thereby generating an expanded population of T cells; introducing into the expanded NK cell population a nucleic acid encoding a genetically modified receptor configured to bind to CD19 expressed by the cancer cells and, upon binding, elicit cytotoxic activity against the cancer cells, to generate genetically modified cytotoxic NK cells; introducing into the expanded T cell population a nucleic acid encoding a genetically modified receptor configured to bind to CD19 expressed by the cancer cells and, upon binding, elicit cytotoxic activity against the cancer cells, to generate genetically modified cytotoxic T cells; generating a mixed population of genetically modified immune cells by combining a portion of said genetically modified cytotoxic NK cells with a portion of said genetically modified cytotoxic T cells, wherein the number of said genetically modified cytotoxic NK cells is combined in a ratio that is at least 5 times greater than the number of said genetically modified cytotoxic T cells; A method comprising:
2. The method of claim 1, wherein the at least one molecule for stimulating the proliferation of NK cells comprises a combination of 4-1BBL and IL-15.
3. The method of claim 2, wherein the IL-15 is membrane-bound to the feeder cells.
4. 4. The method of any one of claims 1 to 3, wherein culturing the isolated first immune cell subpopulation further comprises adding one or more of soluble interleukin 2, soluble interleukin 12, soluble interleukin 18, or a combination thereof to the culture.
5. 5. The method according to claim 1, wherein both the NK cells and the T cells are transformed with a nucleic acid encoding the same chimeric antigen receptor.
6. 5. The method of claim 1 , wherein the NK cells and the T cells are transformed with nucleic acids encoding different chimeric antigen receptors.
7. The method of claim 5, wherein the chimeric antigen receptor comprises an OX40 costimulatory domain and a CD3ζ signaling domain operably linked to an anti-CD19 scFv.
8. 8. The method of claim 5 or 7, wherein the chimeric antigen receptor is encoded by a nucleic acid having at least 95% sequence identity to SEQ ID NO:
1.
9. 8. The method of claim 5 or 7, wherein the chimeric antigen receptor comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO:
2.
10. 10. The method of claim 1, wherein the at least one molecule for stimulating T cell proliferation comprises an anti-CD3 antibody.
11. 11. The method of any one of claims 1 to 10, wherein the at least one molecule for stimulating T cell proliferation comprises an anti-CD28 antibody.
12. The method of any one of claims 1 to 11, wherein the blood sample is a peripheral blood sample.
13. 12. The method of any one of claims 1 to 11, wherein the blood sample is an umbilical cord blood sample.
14. A mixed population of genetically modified immune cells is 8 1 x 10 pieces 10 1 × 10 genetically modified cytotoxic NK cells and 6 1 x 10 pieces 8 14. The method of any one of claims 1 to 13, comprising:
15. 15. The method of claim 14, wherein the mixed population of genetically modified immune cells (i) exhibits a rapid cytotoxic effect against the tumor cells compared to NK cells or T cells alone, followed by an enhanced and persistent cytotoxic effect against the tumor cells, or (ii) exerts a longer lasting cytotoxic effect against the tumor cells compared to NK cells or T cells alone.
Citation Information
Patent Citations
Chimeric antigen receptor and methods of use thereof
JP2018504894A
Methods for Improving Efficacy and Growth of Chimeric Antigen Receptor-Expressing Cells
JP2018516592A
Expansion of NK cells and therapeutic uses thereof
US20060093605A1
Methods and compositions for transducing lymphocytes and regulated expansion thereof
US20170296678A1
Chimeric antigen receptor combination therapy for treating tumors
US20180028633A1
